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ABSTRACT  
The overall aim of this doctoral thesis was to study the outcome and safety of mechanical 
thrombectomy, which is an endovascular technique for treating moderate to severe acute 
ischemic stroke caused by a large cerebral artery occlusion. The technique has been 
developed over the last two decades. At the onset of this doctoral project, only a limited 
numbers of studies on the technique had been published, but the results were very promising.  
This thesis is based on five peer-reviewed publications. In these studies, it was found that: 
• patients with basilar artery occlusions who were treated using mechanical 
thrombectomy (at Karolinska University Hospital between September 2005 – 
November 2010), had a significantly better functional outcome compared to patients 
in other studies, where intravenous thrombolysis or no reperfusion therapy was given 
(Study I).  
• mechanical thrombectomy was a safe and effective method for restoring blood flow in 
selected patients suffering from a moderate to severe acute ischemic stroke that was 
caused by a large artery occlusion (Study II). This was concluded from an 
examination of patients with anterior and posterior circulation strokes who were 
treated with mechanical thrombectomy at Karolinska University Hospital between 
September 2005 – December 2011. 
• neither prior treatment with intravenous thrombolysis, nor advanced age, was 
significantly associated with a risk of symptomatic intracranial hemorrhage (Study II). 
• functional outcome three months after mechanical thrombectomy was equally good 
for those over 80 years of age as for those between 50-64 and 65-79 years of age 
(Study III). This was concluded from an examination of the subgroup of patients from 
study II with anterior circulation stroke, selected according to practice at Karolinska 
University Hospital. 
• in patients with wake-up stroke, there was no indication of poorer outcome (Study 
III).  
• endovascular treatment combined with intravenous thrombolysis led to a higher ratio 
of patients with improved functional outcome compared to patients treated with 
intravenous thrombolysis alone, with an absolute risk reduction of 19% (Study IV). 
This was concluded from a meta-analysis of six randomized controlled trials. 
• the estimated rate of thrombectomy in Sweden in 2013 might have been more than 
five times higher than the actual rate, if patients had been selected according to our 
practice at the Karolinska University Hospital (a practice similar to the recently 
published updated treatment recommendations from both European and American 
organisations) (Study V). This was concluded by comparing treatment proportions at 
our institution by level of stroke severity with stroke data from the rest of Sweden, 
provided from Riksstroke (the Swedish national stroke registry). 
In conclusion, it has been shown that mechanical thrombectomy is a safe treatment, which 
significantly improves the likelihood of functional outcome for patients with moderate to 
severe stroke. The findings indicate that a substantial increase in demand for this treatment 
option should be expected.  The main challenge now is to fully implement the technique in 
clinical practice and to be able to offer it to all patients throughout Sweden, not just to those 
who live in the proximity of a university hospital. 
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1 INTRODUCTION 
 
Mechanical thrombectomy is an endovascular technique to treat moderate to severe acute 
ischemic stroke, when a large artery in the brain is occluded. This technique has been 
developed during the last two decades. At the beginning of this doctoral project there were 
only a limited numbers of studies published about the clinical outcome of this technique, 
although with very promising results. The department of neuroradiology at the Karolinska 
University Hospital adopted the method quite early and the first thrombectomy was 
performed in September 2005. This doctoral project started in June 2010 and by that time the 
department had one of the largest series of performed thrombectomies in Europe. The main 
aim of this doctoral project was to further examine the safety and effectiveness of the method. 
 
 2 
2 BACKGROUND 
 
2.1 WHAT IS STROKE? 
Acute stroke is today the second leading cause of death in the world, responsible for 11% of 
overall mortality.1,2 A stroke occurs either when the blood flow to an area in the brain is 
obstructed by a blood clot in a blood vessel (ischemic stroke) or when a blood vessel ruptures 
in the brain or at the brain’s surface (hemorrhagic stroke). About 85% of all strokes are 
ischemic and the remainder are hemorrhagic.3 In Sweden, about 25 000 people suffer from 
acute stroke every year, with the mean age for stroke approximately 76 years (73 years for 
men and 78 years for women).4 In addition to human suffering, the economic burden for 
treatment and rehabilitation for these patients is obviously very large. 
In this thesis only ischemic stroke is addressed. 
 
2.1.1 Pathophysiology 
When a cerebral artery is occluded, within seconds the cells in the territory supplied by that 
vessel lose basic function such as synaptic transmission, ion pumping and energy 
metabolism, eventually leading to cellular necrosis. The damage is caused by activation of the 
ischemic cascade, which progresses to total depletion of oxygen or glucose, causing failure of 
high energy phosphate compounds like adenosine triphosphate (ATP). This affects energy-
dependent processes necessary for tissue cell survival, and sets off a series of interrelated 
events culminating in cellular injury and death.5  However, total loss of function and 
subsequent development of infarction only occur if the ischemia is complete. If residual 
perfusion persists, due to for example additional blood supply from collateral vessels, an area 
of perfused brain tissue with electrical failure but sustained energy metabolism and normal 
extracellular potassium levels may develop. Astrup et al. described this, in 1981, as ischemic 
penumbra.6 In this “tissue at risk” the perfusion restriction is thought to be severe enough to 
arrest physiological function, but not so complete as to cause irreversible infarction.7-9 If 
revascularisation occurs in time, this penumbral area might regain its function. The concept 
of reversibility encouraged the search for both ways to image the potentially salvageable 
brain tissue10 and for reperfusion treatments.  
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Figure 1. Penumbra. At baseline a small infarct core is already manifest, and a larger 
surrounding area is at risk (penumbra). If reperfusion is achieved in time, the tissue at risk can 
be salvaged. If not, the final manifest infarct will also include the penumbra. 
 
2.1.2 Time and collaterals 
For the stroke population in general, time to reperfusion is of utmost importance.11-14 For the 
specific patient there might be other factors that are as crucial. There is a huge inter-
individual difference in how fast an infarct develops; one patient with an M1-occlusion might 
have a manifest infarct in the entire middle cerebral artery territory after less than one hour 
and another patient, with a similar occlusion, might have salvable tissue after six or even 
eight hours.15 Collaterals, which are alternative ways for blood to reach the target tissue, are 
of great importance.16  Many additional, as yet unknown factors will likely be discovered. 
 
2.1.2.1 Circle of Willis 
The blood vessels for both the left and right hemispheres originating from the internal carotid 
arteries (the anterior circulation) and the blood vessels originating from the vertebrobasilar 
system (the posterior circulation) are connected at the skull base through the circle of 
Willis.17 This circle forms a collateral system and is complete in only 40-50% of all 
Baseline( Final(lesion(size(
Area(at(risk((penumbra)(
Manifest(infarct(
Reperfusion(
No(reperfusion(
 4 
patients.18 This collateral system only helps with an occlusion proximal to the circle. In the 
anterior circulation this would be in the internal carotid artery proximal to the origin of the 
posterior communing artery and in the posterior circulation in or proximal to the P1 segment 
of the posterior cerebral artery. 
 
 
 
Figure 2. Circle of Willis. (Image reprinted with permission from A.D.A.M.) 
 
 
2.1.2.2 Pial collaterals 
There exists a leptomeningeal (pial) collateral network, over the surface of the brain, which 
allows the anterior and posterior cerebral arteries to provide additional blood supply to at 
least part of the territory of the middle cerebral artery (MCA) in case of an MCA-occlusion, 
and vice versa.19 These collateral vessels widely differ in width and number between different 
individuals, and may also develop over time, for example in the case of an intracerebral 
stenosis that reduces flow in one territory.20  
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Figure 3. Pial collaterals. Carotid artery angiogram in frontal projection. The image on the 
right is taken 2 seconds after the image to the left. Note late filling through collateral vessels 
from the anterior cerebral artery to the area usually supplied by the middle cerebral artery.  
 
2.1.2.3 Dural-pial collaterals 
The external system, most notably the external carotid arteries, supplies blood to dural 
(meningeal) and extra cerebral structures. The internal system, the branches called pial 
vessels, originating from the internal carotid and the vertebrobasilar arteries, supplies the 
brain parenchyma. There are several connections between the external and the internal 
systems; one of the most common, seen in cases of stenosis or occlusion of the internal 
carotid artery, is a connection via the ophthalmic artery.17 These connections exist mostly in 
the base of the skull, and therefore only help in cases of proximal occlusion or stenosis.  
 
2.2 IMAGING OF STROKE 
Since there are no physiologic or blood biomarkers for stroke, imaging has evolved as the 
best available method for detection of acute stroke. Many of the advances that have been 
made in the treatment of acute stroke during the last three decades would never have been 
feasible without the advances in neuroimaging. Initially imaging was used merely to exclude 
hemorrhage, in order to determine whether to give intravenous thrombolysis (IVT) or not. 
More recently, imaging is used to try to comprehend and demonstrate the pathophysiology 
behind the acute stroke. In the acute setting, the role of neuroimaging has become to provide 
fast critical diagnostic information that will determine the acute treatment decisions.    
 
Supply 
through 
collateral 
vessels 
 
 
 
 
 
Occlusion 
of left M1  
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2.2.1 Computed tomography 
In the 1990s computed tomography (CT) made it possible to see early signs of cerebral 
infarction, as early as a few hours after onset of symptoms. Since then the technique has 
developed remarkably, and today early signs can often be detected with CT within an hour. 
The main use of unenhanced CT is to exclude hemorrhage before IVT can be given, but also 
to exclude the presence of large manifest infarcts. Signs of early infarction may be 
hypoattenuation, loss of grey-white matter differentiation and localized mass effect, as can be 
observed by so-called sulcal effacement. Sometimes the actual thrombus can be observed as a 
high attenuating structure, as the “dense vessel sign”. These early signs can be difficult to 
detect and there is an interobserver variability, where experience has been shown to improve 
detection.21    
 
 
 
 
 
Figure 4. Axial CT images of the brain. Note dense vessel sign of the left middle cerebral 
artery (left image) and the loss of grey-white matter differentiation around the left putamen 
(middle image). No signs of infarction in the right image. 
 
2.2.2 CT-angiography 
If CT-imaging is performed during administration of intravenous contrast media, the cerebral 
vascular anatomy can be studied. Intravenous contrast is administered by a power injector, 
followed by a saline-injection at the same rate to rapidly push all the contrast into the vascular 
system. Scanning is performed at a single time point after contrast injection, making it a 
Dense vessel sign 
Loss of grey-white 
matter differentiation 
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“snapshot” of the enhanced cerebrovascular anatomy.22 Depending of the timing of the 
acquisition either the arteries or the veins will be visualized best. Due to advances in 
technology, scanning from the aortic arch to the vertex can be completed with a single 
contrast injection in only a few seconds. The great advantage of this technique is the ability to 
evaluate not only the location of an intracerebral occlusion, but also to evaluate the aortic 
arch and cervical vessels in order to diagnose extracranial atherosclerosis, stenoses or 
dissections as well as to plan the interventional procedure. The ability to visualize the 
occlusion site enabled the increasing use of mechanical thrombectomy. 
 
 
 
Figure 5. CT angiography. Occlusion of the left middle cerebral artery (right side in each 
image). The arteries in the left hemisphere, seen beyond the occlusion, are supplied in 
retrograde direction via the anterior and posterior cerebral arteries (collateral flow). 
 
2.2.3 Multiphase CT 
As multidetector CT scanners increased scanning speed in the late 1990s different techniques 
were developed by repeating serial static mode acquisitions during a single contrast injection. 
This has made it possible to scan, for example, first in arterial phase then in venous phase and 
finally in late venous phase.23 Multiphase CT makes it possible to evaluate the status of 
collateral circulation, and might help in selecting patients for thrombectomy and in prediction 
of outcome.23  
 
Left M1 occlusion  Collateral supply 
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2.2.4 CT perfusion 
Continuous scanning mode is a way to further improve the temporal information, by 
repeatedly scanning the targeted region.22 To minimize the higher radiation dose as a result of 
increased scanning, different post-processing techniques were developed. Cerebral perfusion 
can be described by several parameters, of which some are more commonly used. Cerebral 
Blood Flow, CBF, is defined as the volume of blood moving through a given volume of brain 
per unit time, measured in millilitres of blood per 100g of brain tissue per minute. Cerebral 
Blood Volume, CBV, is defined as the total volume of flowing blood present in a given 
volume in the brain, measured in millilitres of blood per 100 g of brain tissue. Mean Transit 
Time, MTT, is the average transit time of blood through a given brain region, and Time To 
Peak, TTP, describes the time required to achieve maximum density of contrast within a 
specific region of brain tissue, both measured in seconds.22,24 Differentiation between the 
infarcted tissue and the penumbra is based on the concept of cerebral vascular autoregulation. 
Infarcted tissue loses its ability to autoregulate, which manifests as matched reduction in CBF 
and CBV with prolonged MTT. On the other hand, penumbra maintains its ability to 
autoregulate, thus CBV is sustained with prolonged MTT.25,26 It has been difficult to establish 
a robust absolute definition of infarct core and penumbra, and several have been suggested - 
absolute CBV,25 the product of absolute CBV and CBF,27 and relative CBF.28 CT perfusion is 
also used for selection of patients for thrombectomy and prediction of outcome. 
 
Figure 6. CT perfusion, attenuation of contrast medium measured in Hounsfield Units (HU) 
plotted against time, describing the different parameters used. (Courtesy of M Kaijser.) 
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 Figure 7. CT perfusion images. Cerebral Blood Flow (CBF) to the left, Cerebral Blood 
Volume (CBV) in the middle, Mean Transit Time (MTT) to the right, all from the same axial 
slice in the same patient. Colour coded scales are not shown in the figure: the two 
hemispheres can be compared with each other. A perfusion defect is seen in the left 
hemisphere (right side on the images), with reduction of CBF and prolonged MTT, but with 
maintained CBV (penumbra). 
 
 
2.2.5 Magnetic Resonance Imaging 
Although many centres prefer CT in stroke evaluation, due to the speed and availability, 
others prefer magnetic resonance imaging (MRI) due to its superior ability to assess the 
infarct core with diffusion sequences.29,30 One disadvantage with MRI is that it may be time 
consuming. Even if the actual scanning time can be reduced, it often takes time to get the 
patient into the scanner. Contraindications for MRI, such as pacemaker or other metal 
objects, must be assessed. If the patient has difficulties in understanding instructions and to 
remain still it may be difficult to obtain high quality images, since they usually are acquired 
over several minutes. In such cases sedation or general anaesthesia may be needed, which 
also adds extra time and risk. One situation where MR is an especially valuable tool is in 
posterior circulation strokes, since it may be difficult to evaluate ischemic changes in the 
brainstem on CT.  
The type of imaging (CT or MRI) used in the work up of stroke in practice may be most 
dependent on local organizational factors and availability.31 
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Figure 8. MRI at the level of pons and cerebellum. Diffusion Weighted Image (DWI) in the 
left image and Apparent Diffusion Coefficient (ADC) in the right image, demonstrating an 
area of restricted diffusion, as in a large infarction, in the pons.  
 
2.3 BASELINE AND OUTCOME MEASUREMENTS 
There are several ways to measure severity as well as short and long term outcomes of stroke. 
A variety of rating scores are commonly used. In this section a selection will be described. 
 
2.3.1 Stroke severity 
A widely used scale for assessing stroke severity is the National Institutes of Health Stroke 
Scale (NIHSS) score.32,33 Points are given for level of consciousness, orientation, ability to 
obey command, gaze problems, visual loss, facial palsy, motor function in arm and leg, limb 
ataxia, sensory loss, dysphasia, dysarthria, and neglect etc. (figure 9). The score correlates 
best to the severity of stroke in the anterior circulation. Stroke in the posterior circulation can 
be severe without effect on NIHSS score.34 The currently NIHSS is composed of eleven main 
items and it ranges from 0 to 42, in which 0 means absence of neurological symptom and 42 
corresponds to maximum severity. 
The Glasgow Coma Scale (GCS) was described in 1974, as a way to describe the level of 
consciousness of patients with an acute brain injury.35,36 The scale is divided in three parts 
testing eye opening, verbal response and motor response, with a minimum of 3 points (coma) 
and a maximum of 15 points (normal status, alert) (figure 10). The GCS may be useful, 
especially for patients with posterior circulation stroke in which varying levels of 
consciousness is among the potential symptoms.37 
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Figure 9. The National Institutes of Health Stroke Scale, NIHSS. (Image created by the 
author of this thesis) 
 
 
The National Institutes of Health Stroke Scale 
Category Score/Description Score 
1a. Level of Consciousness 0 = Alert; keenly responsive                                           
1 = Arouses to minor stimulation                                   
2 = Requires repeated stimulation to arouse                    
3 = Unresponsive, coma 
 
1b. LOC Questions (Month, 
age) 
 
0 = Answers both correctly                                              
1 = Answers one correctly                                              
2 = Incorrect 
 
1b. LOC Commands 
(Open/close eyes, squeeze hands) 
0 = Obeys both correctly                                                  
1 = Obeys one correctly                                                  
2 = Incorrect 
 
 2. Best Gaze                         
(Eyes open – patient follows 
examiner´s finger or face) 
0 = Normal                                                                      
1 = Partial Gaze Palsy                                                     
2 = Forced deviation 
 
3. Visual Fields             
(Introduce visual stimulus/threat 
to patients visual field quadrants) 
0 = No visual loss                                                             
1 = Partial Hemianopia                                                    
2 = Complete Hemianopia                                              
3 = Bilateral Hemianopia (Blind) 
 
4. Facial Paresis                  
(Show teeth, raise eyebrows and 
squeeze eyes shut) 
0 = Normal                                                                      
1 = Minor                                                                         
2 = Partial                                                                         
3 = Complete 
 
5a Motor Arm – Left 
5b Motor Arm – Right 
(Elevate arm to 90° if patient is 
sitting, 45° if supine) 
0 = No drift                                                                      
1 = Drift                                                                            
2 = Can´t resist gravity                                                         
3 = No effort against gravity                                                
4 = No movement                                                             
x = Untestable (joint fusion or amputation) 
Left  
 
Right  
6a Motor Leg – Left 
6b Motor Leg– Right 
(Elevate leg 30° with patient 
supine) 
0 = No drift                                                                      
1 = Drift                                                                            
2 = Can´t resist gravity                                                         
3 = No effort against gravity                                                
4 = No movement                                                             
x = Untestable (joint fusion or amputation) 
Left  
 
Right  
7. Limp ataxia                  
(Finger-nose, heel down shin) 
0 = No ataxia                                                                      
1 = Present in one limb                                                     
2 = Present in two limbs 
 
8. Sensory                                
(Pin prick to face, arm, trunk and 
leg – compare sides) 
0 = Normal                                                                      
1 = Partial Loss                                                             
2 = Severe loss 
 
9. Best language                 
(Name items, describe a picture 
and read a sentence) 
0 = No aphasia                                                               
1 = Mild to moderate aphasia                                                    
2 = Severe aphasia                                                        
3 = Mute 
 
10. Dysarthria                
(Evaluate speech clarity by 
patient repeating listed words) 
0 = Normal articulation                                                
1 = Mild to moderate alluring of words                                                   
2 = Near to unintelligible or worse                                                        
x = Intubated or other physical barrier 
 
11. Extinction and Inattention        
(Use information from prior 
testing to identify neglect or 
double simultaneous stimuli 
testing) 
0 = No neglect                                                                     
1 = Partial neglect                                                                                                                                
2 = Complete neglect  
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Glasgow Coma Scale 
Category Score/Description Score 
Best eye response (E) 1 = None      
2 = To pressure 
3 = To speech 
4 = Spontaneous 
                   
Best verbal response (V) 1 = None  
2 = Sounds 
3 = Words 
4 = Confused   
5 = Oriented  
 
Best motor response (M) 1 = None  
2 = Extension 
3 = Abnormal flexion 
4 = Normal flexion (withdrawal)  
5 = Localising                 
6 = Obeying commands 
 
 
Figure 10. Glasgow Coma Scale, GCS.36 (Image created by the author of this thesis) 
 
 
 
2.3.2 Size of early ischemic lesion/manifest infarct 
In the European Cooperative Acute Stroke Study (ECASS) trial patients were excluded from 
IVT if early ischemic findings exceeded one third of the MCA territory.38,39 Unfortunately, 
later research has shown that even experienced radiologists and stroke physicians have 
difficulties both to correctly interpret early ischemic lesions on CT and to quantify them 
reliably.21,40-42 In order to create a more reliable and reproducible grading system, the Alberta 
Stroke Program Early CT Score (ASPECTS) was suggested by Pexman et al. in 2001.43 
ASPECTS is a 10-point scale that rates the presence or absence of ischemia in 10 regions of 
the middle cerebral artery territory (figure 11). A normal CT scan receives an ASPECTS of 
10 points; a single point is subtracted for every area with early ischemic change, visualized as 
focal swelling or parenchymal hypoattenuation.  
ASPECTS can be applied both before and after reperfusion therapy, in order to evaluate 
tissue outcome. 
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Figure 11. The ten included areas of ASPECTS. C – Caudate nucleus, L - Lentiform nucleus, 
IC - Internal Capsule, I – Insular cortex, M1, M2, M3 - middle cerebral artery territory at the 
level of the basal ganglia, M4, M5, and M6 - middle cerebral artery territory at the level of 
cella media and above. (Image reprinted with permission from aspectsinstroke.com) 
 
2.3.3 Reperfusion 
Technical results after thrombectomy are most often rated by a grading score of reperfusion 
or revascularization as seen on cerebral angiography. At first a scale adopted from coronary 
angiography, the Thrombolysis In Myocardial Infarction (TIMI) scale, or variants thereof, 
was used.44 Later, the TIMI scale was transformed into the Thrombolysis in Cerebral 
Infarction (TICI) scale, adapted to the cerebral circulation,45 further modified into the 
modified TICI (mTICI) scale46 by the Interventional Management of Stroke (IMS) study 
investigators. The mTICI scale differs from the TICI scale in the definition of the score 2a 
and 2b, where the modified scale uses perfusion of less than or more than 50% of the MCA-
territory and the TICI scale has less than or more than 2/3 as a cut off. Later, an extra sub 
classification 2c was added.47 The different scales make it difficult to compare studies, and 
Zaidat et al made an attempt to uniform the grading in 2013, in which they recommended the 
use of mTICI (grade 0, 1, 2a, 2b and 3), but changed the meaning of the acronym to modified 
Treatment In Cerebral Ischemia, acknowledging that treatment consists not only of 
thrombolysis (figure 12).48 
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Modified Treatment in Cerebral Ischemic Scale 
Score Definitions 
  0 No perfusion 
  1 Antegrade reperfusion past the initial occlusion, but limited distal branch filling with 
little or slow distal reperfusion. 
  2a Antegrade reperfusion of less than half of the occluded target artery previously 
ischemic territory (e.g., in 1 major division of the MCA and its territory) 
  2b Antegrade reperfusion of more than half of the previously occluded target artery 
ischemic territory (e.g., in 2 major division of the MCA and their territories) 
  3 Complete antegrade reperfusion of the previously occluded target artery ischemic 
territory, with absence of visualized occlusion in all distal branches. 
 
Figure 12. Modified Treatment in Cerebral Ischemia Scale, mTICI.48 (Image created by the 
author of this thesis) 
 
 
 
2.3.4 Functional outcome 
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of 
disability in the daily activities of people who have suffered from a stroke, in most studies 
evaluated after 3 months. The scale was originally introduced in 1957 by Dr John Rankin 
from Glasgow, Scotland,49 and later modified for use in the United Kingdom transient 
ischaemic attack (UK-TIA) trial in the late 1980s (figure 13).50 This scale can be used in 
several different ways, either dichotomised in different cut-off level groupings such as mRS 
0-1 representing excellent outcome, mRS 0-2 representing good outcome or functional 
independence, or mRS 5-6 as poor outcome, compared to the rest of the scores in the scale 
(mRS 2-6, mRS 3-6 and mRS 0-4 respectively). The mRS can also be used in shift analysis, 
in which a shift towards better or worse outcome across the scale is compared between the 
studied groups.51 An advantage of shift analysis is the ability to detect shifts or changes in the 
middle of the mRS spectrum, which might be clinically meaningful. 
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The modified Rankin Scale, mRS 
Score Definition 
  0 No Symptoms 
  1 No significant disability. Able to carry out all usual activities, despite some symptoms. 
  2 Slight disability. Able to look after own affairs without assistance, but unable to carry 
out all previous activities. 
  3 Moderate disability. Requires some help, but able to walk unassisted. 
  4 Moderately severe disability. Unable to attend to own bodily needs without assistance 
or unable to walk unassisted. 
  5 Severe disability. Requires constant nursing care and attention, bedridden. 
  6 Dead 
 
Figure 13. The modified Rankin Scale, mRS. (Image created by the author of this thesis) 
 
 
Another commonly used scale measuring functional outcome is the Barthel index (BI), 
developed in 1965 and modified by Granger et al. in 1979.52 BI measures the patient’s 
performance in ten activities of daily living (feeding, grooming, bathing, dressing, bowel and 
bladder care, toilet use, ambulation, transfers, and stair climbing), with a maximum score of 
100. The lowest score is 0, representing a totally bedridden state. The BI measures 
performance of specific tasks, rather than independence – as measured by the mRS. Both 
scales are easy to use, have acceptable degree of reliability, and both have been used in 
several studies.52  
There are several other scales measuring outcome after stroke, but in our studies we chose to 
use only the mRS scale. 
 
2.3.5 Symptomatic intracranial hemorrhage 
Asymptomatic hemorrhagic transformation, usually small petechiae at the edges of the infarct 
or within the infarcted area, is often seen when successful recanalization has occurred and is 
thought to be without clinical impact.53 When a hemorrhage causes clinical deterioration, it is 
classified as symptomatic intracranial hemorrhage (SICH), which is the most common 
reported severe adverse event. In our studies we have reported SICH according to the SITS-
MOST (Safe Implementation of Thrombolysis in Stroke–Monitoring Study) definition: an 
intracerebral hemorrhage exceeding 30% of the infarcted volume with significant space 
occupying effect on the post-treatment imaging scan leading to a decline in NIHSS score of  
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≥ 4 points or causing death within 36 h.54 There are several other definitions used in different 
trials, which makes comparison between studies more difficult. In the National Institute of 
Neurological Disorders and Stroke (NINDS) trial any CT-documented hemorrhage that was 
temporally (within the first 36h) related to any decline in the patients neurological status, 
judged by the clinical investigator, was defined as SICH.55 In PROACT (Prolyse in Acute 
Cerebral Thromboembolism) II the definition was hemorrhagic transformation within 24 
hours causing a decline in NIHSS score of ≥ 4 points or a 1-point deterioration in level of 
consciousness.56 In ECASS III any apparently extravascular blood within the cranium 
identified as the predominant cause of neurological deterioration (defined as a decline in 
NIHSS score of ≥ 4 points or leading to death) was regarded as SICH.57  
 
2.3.6 Mortality 
The proportion of deaths during a specified time period, case fatality rate, is the most 
commonly used measurement.  Most publications use the number of deaths at 3 months after 
treatment. Since most authors include all deaths during this time period, not only those 
caused by stroke, we chose to do the same.  
 
2.4 TREATMENT OF STROKE  
Since time immemorial stroke has been a devastating disease, with little to do but to accept 
and to make the most of whatever function is remaining. Fortunately, much progress has been 
made during the last four decades, and up till the present time three eras in the evolution of 
modern ischemic stroke care can be discerned. The first era was characterised by stroke 
specific care and the development of specialized stroke units. Next came the era of 
intravenous thrombolysis, and most recently the era of endovascular mechanical 
thrombectomy.  
 
2.4.1 Specialized stroke units 
In the 1980-1990s several studies comparing specialized stroke units with general medical 
wards were published.58-61 Stroke units emphasized the value of a team approach to nursing 
and rehabilitation and the importance of starting rehabilitation early. Stroke unit treatment 
was shown to reduce the length of hospital stay, reduce the need for institutional care and in 
some of the studies also to decrease in mortality rates.61 The beneficial effect of stroke unit 
care has been confirmed in several studies.62,63 The convergence of multidisciplinary 
treatment, monitoring and care in dedicated stroke units prevents complications, improves 
functional outcomes and reduces stroke mortality. 
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2.4.2 Intravenous thrombolysis 
Intravenous thrombolytic drugs were first used in the late 1950s for acute stroke.64 Up to the 
early 1990s several case series, open trials and some randomized trials were performed, most 
of which were small with heterogeneous inclusion criteria and treatment. Therefore there 
were no clear evidence of either positive or negative effects of intravenous thrombolysis, and 
there was a fear of hemorrhagic transformation.65 It was not until the second half of the 1990s 
that the new treatment gained more widespread interest. 
 
2.4.2.1 Randomized trials in the 1990s 
There were several randomized controlled studies conducted during the 1990s, involving 
streptokinase and alteplase (tissue plasminogen activator, tPA). Results from randomized 
trials of intravenous treatment with streptokinase were nonfavourable, including an increase 
in mortality.66,67 Results with alteplase were mixed,38,39,55,68,69 but overall showed a time-
dependent benefit.70,71 
In 1995, Hacke et al. published “Intravenous thrombolysis with recombinant tissue 
plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke 
Study (ECASS)” in the Journal of the American Medical Association (JAMA).38 The study 
was randomized and included 640 patients from 14 different European countries 
demonstrating that in a selected population, including patients with moderate to severe 
neurologic deficit and without extended infarct signs on the initial CT scan, treatment with 
alteplase within six hours from stroke onset could improve outcome.  Reassuringly they did 
not find any statistically significant differences in the mortality rate at 30 days or in the 
overall incidence of intracerebral hemorrhages. However, the occurrence of large 
parenchymal hemorrhages was significantly more frequent in the group treated with alteplase.  
The same year, New England Journal of Medicine (NEJM) published the results from another 
randomized trial, “Tissue plasminogen activator for acute ischemic stroke”, performed by the 
NINDS rt-PA Stroke Study Group.55 This study assessed the efficacy and safety of rt-PA 
when given within three hours from stroke onset, using a lower dose of alteplase than was 
used in the ECASS study (0.9 mg/kg bodyweight instead of 1.1 mg/kg). Despite an increased 
incidence of symptomatic intracerebral hemorrhage, patients receiving rt-PA were at least 
30% more likely to have minimal or no disability at 3 months than those who received 
placebo. 
On the basis of the NINDS-study, alteplase was approved in the United States of America 
(USA) for use within three hours of onset of symptoms.39 
In 1998, results were published from a new randomized trial, ECASS II, in which patients 
were treated with the same dose of alteplase as used in the NINDS-trial, but with a time-
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window of 6 h. In this study patients with signs of early infarct involving more than one third 
of the middle cerebral artery territory were excluded.39 The study did not confirm a statistical 
benefit for alteplase when mRS 0-1 was regarded as favourable outcome. Still, the authors 
(Hacke et al.) believed that the trend they found towards efficacy should be interpreted in the 
light of evidence from previous trials. A post-hoc analysis was also performed, in which mRS 
0-2 was used as end-point (not predefined), and then there was a statistically significant 8.3% 
absolute difference in favour of alteplase. Despite the increased risk of intracranial 
hemorrhage the authors proposed that thrombolysis with alteplase at a dose of 0.9 mg/kg in 
selected patients could lead to a clinically relevant improvement in outcome. 
A year later data from the Alteplase ThromboLysis for Acute Noninterventional Therapy in 
Ischemic Stroke (ATLANTIS) part B was published, failing to find a treatment benefit for 
tPA given 3 to 5 hours after symptom onset.68 In 2002 results from treatment within 3 hours 
were published, supporting the recommendation for early treatment since those patients had a 
more favourable outcome.69  
 
2.4.2.2 Consequences 
During this time period stroke care underwent a transformation. Prior to this, acute stroke 
patients were mostly just observed and provided supportive measures, but now acute 
treatment and the idea of  “time is brain” came into focus. Alteplase was licensed for the 
treatment of acute ischemic stroke in the USA in 1996, and in Canada in 1999, for selected 
patients treated within 3 h of symptom onset. In the European Union (EU), a licence was 
granted in 2002 on two conditions: the establishment of an observational safety study, the 
Safe Implementation of Thrombolysis in Stroke–Monitoring Study (SITS-MOST) to assess 
the safety profile of alteplase in routine clinical practice within 3 h of the onset of stroke 
symptoms,54 and the initiation of a new randomised trial, the European Cooperative Acute 
Stroke Study (ECASS) III, with a therapeutic window extended beyond 3 h.57 The results of 
both studies were to serve as a basis for the reassessment of the benefit/risk profile of 
alteplase for the thrombolytic treatment of acute ischemic stroke in the EU.  
In Sweden in 2005, only 3,3% of all stroke patients were given IVT according to the annual 
report from the Swedish National Stroke Register (Riksstroke).72  
 
2.4.2.3   Confirmation 
In 2007, results from SITS-MOST, an observational study with 6483 patients from 285 
centres in 14 countries, confirmed that intravenous alteplase was safe and effective in routine 
clinical use when used within 3 h of stroke onset.54  
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2.4.2.4   Time-window 
In 2004, a pooled analysis of ATLANTIS, ECASS AND NINDS rt-PA stroke trials 
confirmed the association between rapid treatment with intravenous thrombolysis and 
favourable outcome, and suggested a potential benefit up to 4.5 h after symptom onset, 
although not as effective as early treatment, up to three hours.70 
In 2008, ECASS III (a double-blind, parallel-group trial that enrolled patients from multiple 
centres across Europe) showed that intravenous alteplase administered between 3 and 4.5 
hours after the onset of symptoms significantly improved clinical outcomes in patients with 
acute ischemic stroke, but that alteplase was more frequently associated with symptomatic 
intracranial hemorrhage.57 
The same year, additional results from the observational study SITS-ISTR (SITS-
International Stroke Treatment Registry) demonstrated that alteplase remained safe when 
given at 3-4.5 h after ischemic stroke.73 
In 2010 Lee et al. made an updated pooled analysis of ECASS, ATLANTIS, NINDS, and 
Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) trials and concluded that 
patients with ischemic stroke selected by clinical symptoms and CT benefit from intravenous 
alteplase when treated up to 4.5 h.11 For maximal benefit every effort should be taken to 
shorten delay in initiation of treatment; beyond 4.5 h, risk might outweigh benefit. They 
found that depending on the time of onset 5-15 patients have to be treated in order to have an 
excellent outcome for one individual. In 2012, Wardlaw et al. performed a systematic review 
and meta-analysis of 12 randomized trials, supporting the evidence that some patients might 
benefit up to 6 hours after symptom onset, but showing that the benefit was greatest in 
patients treated within 3 hours.71 
 
2.4.2.5 Age 
The randomized trials described above included a very limited number of patients aged >80 
years. In effect, the ECASS trials specifically excluded this age group,38,39 and the license for 
alteplase in the European Union therefore excluded this age group. The third International 
Stroke Trial (IST-3), published in Lancet 2012, included more than 3000 patients, of whom 
53% were older than 80 years of age; the results supported that the benefits of IVT did not 
seem to be diminished in elderly patients.74 In recent years the effectiveness and safety of 
thrombolysis in the elderly have been addressed in systematic reviews75 and meta-analyses,76 
in registry based observational studies from SITS-ISTR77 and VISTA (the Virtual 
International Stroke Trials Archive)78 as well as in controlled comparison of SITS-VISTA.79 
The overall results indicate generally poorer outcome in this age group compared to younger 
patients, but with an association between thrombolysis and outcome similar to that for 
younger age groups. 
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2.4.2.6 Summary  
Thanks to intravenous thrombolysis, stroke care has developed over a 20 years period from 
being a “low-priority” disease to an acute emergency necessitating high priority and fast 
action. Since the time window for IVT was extended from the initial 3 hours up to 4.5, more 
patients were eligible for care. In Sweden the proportion of stroke patients that were given 
IVT had increased to 12% in 2014 (compared with 3% in 2005).4 Still, many stroke patients 
do not benefit from treatment and the number of stroke patients needed to treat to obtain one 
positive outcome (NNT) remains high. The search for alternative or complementary methods 
has consequently continued parallel to the development of intravenous thrombolysis.  
 
2.4.3 Intra-arterial thrombolysis 
Three randomized trials have found that intra-arterial infusion of recombinant prourokinase 
or urokinase within 6 hours of onset has some effect.56,80,81 In all three trials the stroke had to 
be caused by an occlusion of the middle cerebral artery, M1- or M2-segment. In Prolyse in 
Acute Cerebral Thromboembolism (PROACT)80 and PROACT II56 both the intervention 
group and the control group were treated with heparin bolus and 4 hour infusion, and in the 
Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT)81 only with 
a bolus. In PROACT, the intervention group received intra-arterial infusion, of 6 mg 
recombinant prourokinase in the thrombus infused over two hours, and the control group 
received intra-arterial placebo. In PROACT II the dose was 9 mg infused over two hours, but 
no infusion was given to patients in the control group. In MELT various doses of urokinase 
were given intra-arterially to the intervention group. PROACT showed increased 
recanalization rate after intra-arterial treatment (IAT) compared to heparin alone, and 
PROACT II showed increased rate of favourable clinical outcome (mRS 0-2). MELT failed 
to show benefit in its primary endpoint (mRS 0-2), but showed increase in excellent outcome, 
mRS 0-1.  
Since the control groups were not given intravenous thrombolysis it is not known whether 
IVT in this design would have had better outcome than IAT, as questioned in a meta-analysis 
by WJ Powers.82 One of the problems regarding IAT is the long procedure time; an infusion 
of fibrinolytic agents took 2 hours in all of these studies. 
 
2.4.4 Mechanical thrombectomy 
The idea of removing the thrombus mechanically emerged gradually and in small scale. 
There were attempts made with surgical operation, for example at the Mayo Clinic, presented 
in1985.83 Early endovascular attempts were made, one of them in Gothenburg in Sweden, 
where Dr. Gunnar Wikholm was one of the first to develop a technique to perform 
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mechanical embolectomy in cerebral vessels. The first attempts were on cases in which a 
thromboembolic complication had occurred during an endovascular procedure of other cause, 
published already 1998,84 and later performed on patients with primary acute ischemic 
stroke.85 A snare (Amplatz GooseNeck) was introduced through a micro catheter to entrap the 
embolus. The results were good, and in Gothenburg this technique has been used with 
success.86 Another early attempt was made by the use of a basket (Neuronet), presented by 
Mayer in 2002,87 but there were also other variants such as the InTime and the EnSnare.88 
 
  
 
Figure 14. The Amplatz GooseNeck Snare. (Image reprinted with permission from 
Medtronic) 
 
2.4.4.1 The Merci Retriever 
The Merci Retrieval System was specifically designed and developed for percutaneous 
thromboembolectomy in brain vasculature.89 It consists of a tapered wire with 5 helical loops 
of decreasing diameter (from 2.8 mm to 1.1 mm) at its distal end, to be advanced through the 
microcatheter in its straight configuration and resume its helical shape once delivered into the 
occluded intracranial artery, in order to ensnare the thrombus. In the Mechanical Embolus 
Removal in Cerebral Ischemia (MERCI) trial they also used a Balloon Guide Catheter (BCG) 
with a balloon inflated in the internal carotid artery during thrombectomy in order to cause 
occlusion and through aspiration via the guide catheter reverse the blood flow and thereby 
reduce the risk of distal embolization.  
 
 
 
Figure 15. The Merci Retriever.* (Image reprinted with permission from Stryker)  
                                                
* The Merci Retriever was also referred to as “the corkscrew”, due to its characteristic shape. 
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The safety and efficacy of the Merci Retriever to open occluded intracranial large arteries 
within 8 hours of the onset of stroke symptoms was reported in 2005.90 All patients were 
ineligible for IVT. Recanalization was achieved in 46%, with significantly better outcome 
and lower mortality in the group with successful recanalization (mRS 0-2 in 46% versus 
10%, mortality 32% versus 54%) compared to patients with unsuccessful recanalization. In 
2006, Smith et al. reported further results from the MERCI study in the American Journal of 
Neuroradiology (AJNR). They had shown that mechanical thrombectomy after IVT was as 
safe as mechanical thrombectomy alone.91 
 
2.4.4.2 Aspiration 
An alternative mechanical approach was introduced by The Penumbra System, which 
combined aspiration and extraction.92 Aspiration was performed with a reperfusion catheter 
and an aspiration pump, which created a vacuum. On the same time a separator was advanced 
into the proximal thrombus. As an option thrombus could be extracted with a thrombus 
removal ring. Results presented 2009 by The Penumbra Pivotal Stroke Trial Investigators 
showed revascularization (TIMI 2 to3) in 82%, mRS 0-2 in 25%, and a mortality of 33%.93 
Later results using the Separator 3D were more promising with mRS 0-2 in 43% at 90 days.94 
 
 
 
Figure 16. The Penumbra separators and aspiration pump. (Image reprinted with permission 
from Penumbra Inc) 
 
 
2.4.4.3 Stent-retrievers 
A different kind of thrombectomy device was also developed in the form of a microcatheter-
delivered highly flexible, fully retrievable intracranial stent.95 When it was developed, the 
purpose was for endovascular treatment of intracranial aneurysms. The difference from most 
other intracranial stents was its ability to be retrieved and repositioned after complete 
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delivery. In 2008 and 2009, there were anecdotal reports of using the stent for thrombectomy, 
with good results.96,97 Early results for the use of the Solitaire stent as a thrombectomy device 
were described in 2009 and 2010.97,98 Later, there were several case series and studies 
conducted, all of which with promising results.99-106 The Solitaire was later followed by 
several other variants of stent-retrievers, for example the Trevo device.107-110 
 
 
 
 
 
Figure 17. The Solitaire device (above) and the Trevo device (below). (Image reprinted with 
permission from Medtronic (Solitaire) and Stryker (Trevo)) 
 
 
In 2012, Davalos et al. published a retrospective study of 141 consecutive patients in six 
experienced European centres presenting with acute ischemic stroke treated with Solitaire FR 
as the first-line device to restore blood flow.111 Revascularization was achieved in 85%, and 
mRS 0-2 in 55%, with lower mortality (20%) and less symptomatic hemorrhage (4%) than in 
the MERCI study (7.8%). 
That same year (2012) results were also published from two randomized trials comparing the 
Merci Retriever with two different stent retrievers, Solitaire and Trevo.112,113 Saver et al. 
performed the SWIFT (Solitaire With the Intention For Thrombectomy) trial with the primary 
endpoint TIMI 2 or 3 flow in all treatable vessels without symptomatic intracranial 
hemorrhage, which was achieved more often in the Solitaire group than in the Merci group 
(61%vs 24%).112 More patients had good 3-months neurological outcome with Solitaire than 
with Merci (58% vs. 33%) and 90-day mortality was lower (17% vs. 38%). Nogueira et al. 
reported the results from Thrombectomy REvascularization of large Vessel Occlusions in 
acute ischemic stroke (TREVO) II in the same issue of Lancet.113 The primary efficacy 
endpoint, TICI scores of 2 or 3 with the assigned device alone, was met in 86% of the 
patients in the Trevo group and in 60% of the patients in the Merci group. The incidence of 
the different procedure-related complications (primary safety endpoint) did not differ 
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significantly between the groups, 13 (15%) patients in the Trevo group vs. 21 (23%) in the 
Merci group.  
 
2.4.4.4 Randomized trials, 2013 
In March 2013, three randomized trials were published in the New England Journal of 
Medicine.114-116 All of them failed to show superiority of endovascular treatment compared to 
standard treatment (including IVT). In the Mechanical Retrieval and Recanalization of Stroke 
Clots Using Embolectomy (MR RESCUE) the aim was to evaluate mechanical 
thrombectomy, with either Merci Retriever or Penumbra System in two different groups of 
patients, with or without favourable penumbral pattern (determined by imaging), compared to 
standard treatment.114 Patients were to be included within 8 hours after onset of large vessel, 
anterior circulation stroke. In the Interventional Management of Stroke (IMS) III study 
patients who had received IVT within 3 hours after symptom onset were randomly assigned 
to receive additional endovascular therapy or IVT alone.115 In the Local versus Systemic 
Thrombolysis for Acute Ischemic Stroke (SYNTHESIS) study, patients were randomly 
assigned to either endovascular therapy (IAT, mechanical clot disruption or retrieval) or IVT, 
within 4.5 hours after onset.116 
These three trials have all been questioned, for a number of different reasons.117-123 In MR 
RESCUE 22 participating centres enrolled 118 patients during the period from 2004 through 
2011. On average, each participating centre enrolled 1 patient every 16 months, which may 
suggest that inclusion in the trial was selective and not representative of patients with stroke 
in general. The rate of good outcome was also substantially lower for both treatment methods 
(19% in MR RESCUE compared to 42 and 44% in IMS III and SYNTHESIS respectively), 
which makes evaluation of a diagnostic tool (imaging-based penumbral pattern) 
questionable.120 The number of patients per centre per year was small also in the other two 
trials. In both IMS III and SYNTHESIS, patients were randomized partly without 
radiological proof of an occluded vessel, and there was no evaluation of the salvageable brain 
with perfusion CT or MR. In all these 3 trials mainly older devices, Merci or Penumbra, were 
used, and many patients only received intra-arterial thrombolysis instead of thrombectomy. 
The impact of these three trials published in the same issue of NEJM was substantial. In the 
United States, insurance companies were considering withdrawal of reimbursement for 
thrombectomy devices for all ischemic stroke patients.124  The studies also sparked an intense 
research effort, where efforts were made to avoid the design flaws in the trials mentioned 
above.  
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2.4.4.5 Randomized trials, 2015 
In early 2015, five new randomized trials were reported.125-129 The first one to be published 
was the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands (MR CLEAN), published in January 2015, with 
preliminary results presented in October 2014.125 Eligible patients had a confirmed proximal 
occlusion in the anterior circulation and could be treated intra-arterially within 6 hours after 
symptom onset. The study included 500 patients, and convincingly demonstrated superiority 
for mechanical thrombectomy by stent retriever together with standard treatment (89% IVT) 
compared with standard treatment (90% IVT alone). The primary outcome was mRS 0-2 at 
90 days, where the results were 32.6% vs. 19.1%, in favour of endovascular treatment. There 
were no statistically significant differences in mortality or in the occurrence of symptomatic 
intracerebral hemorrhage between the two groups. 
After the announcement of the results from MR CLEAN several other randomized trials were 
halted and interim analyses were performed. Since the results were in significant favour for 
mechanical thrombectomy, four trials were stopped early and the results published.  
The Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion 
with Emphasis on Minimizing CT to Recanalization Times (ESCAPE) trial included patients 
with a proximal intracranial occlusion in the anterior circulation up to 12 hours after 
symptom onset.126 They compared standard care (control group) to standard care plus 
endovascular treatment at 22 centres worldwide, and included 316 patients. Eligible patients 
had an occluded proximal cerebral artery in the anterior circulation, ASPECTS 6-10 and 
moderate to good collateral circulation, defined as filling of 50% or more of the pial arterial 
MCA circulation on CT angiography (preferably multiphase). The rate of functional 
independence was increased in the intervention group (53.0%) compared to the control group 
(29.3%), and the intervention was associated with reduced mortality (10.4%) vs. the control 
group (19.0%). 
The Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment 
(SWIFT-PRIME) trial was performed at 39 centres in the United States and Europe, and 
included 196 patients.127 Patients with confirmed occlusions in the proximal anterior 
intracranial circulation and an absence of large ischemic-core lesions, who were receiving or 
had received intravenous tPA, were assigned to tPA alone (control group) or to undergo 
additional endovascular thrombectomy with the use of a stent retriever within 6 hours after 
symptom onset. Modified Rankin scale score 0 to 2 at 90 days was higher in the intervention 
group than in the control group (60% vs. 35%). There were no statistically significant 
between-group differences in 90-day mortality (9% vs. 12%) or symptomatic intracranial 
hemorrhage (0% vs. 3%). 
The Extending the Time for Thrombolysis in Emergency Neurological Deficits – Intra-
Arterial (EXTEND-IA) trial, performed in Australia and New Zealand, tested whether more 
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advanced imaging selection, recently developed devices and earlier intervention would 
improve outcome.128 All 70 patients received IVT within 4,5 hours after symptom onset and 
were randomized to either IVT alone or combined with endovascular treatment. All the 
patients had occlusion of the internal carotid or middle cerebral artery, evidence of 
salvageable brain tissue and ischemic core of less than 70 ml on CT perfusion imaging. The 
trial was stopped early because of efficacy after 70 patients had undergone randomization (35 
patients in each group). Functional independence at 90 days was 71% in the intervention 
group and 40% in the group receiving IVT alone, without any significant differences in rates 
of death or symptomatic intra cerebral hemorrhage. 
The Randomized Trial of Revascularization with Solitaire FR Device versus Best Medical 
Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel 
Occlusion Presenting within Eight Hours of Symptom Onset (REVASCAT) was a study 
conducted at four centres in Catalonia, Spain, and included 206 patients.129 Treatment had to 
start within 8 hours and mechanical thrombectomy was considered if IVT was ineffective or 
contraindicated. The control group consisted of medical treatment alone (IVT if eligible). 
Modified Rankin Scale score 0-2 at 90 days was 43.7% vs. 28.2%, in favour of intervention. 
After the publication of these five trials with positive results for mechanical thrombectomy 
several meta-analyses have been performed, confirming the results.130-135 The meta-analyses 
showed clear evidence for improvement in functional independence with endovascular 
thrombectomy compared with standard medical care.  
 
2.4.4.6 Consequences 
After the initial three randomised trials were presented with non-favourable results for 
mechanical thrombectomy, five more randomized trials have refuted these initial results. This 
led to a rapid change of treatment recommendations for mechanical thrombectomy after acute 
stroke, supported by the European Stroke Organisation (ESO), European Society of 
Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology 
(ESNR), and European Academy of Neurology (EAN).136 The changes were that mechanical 
thrombectomy, in addition to IVT when eligible, is now recommended treatment for acute 
stroke patients with a large artery occlusion in the anterior circulation within 6 hours from 
stroke onset. Thrombectomy should be performed as soon as possible. If IVT is 
contraindicated, mechanical thrombectomy should be performed as first-line treatment. 
Patients with basilar artery occlusion could also be treated with thrombectomy, or treated 
within a randomized trial (approved by local ethical committee). The American Heart 
Association/American Stroke Association (AHA/ASA) has also published new treatment 
recommendations, in which thrombectomy is recommended in large artery occlusions 
(internal carotid artery (ICA) or proximal MCA) within 6 h of symptom onset and with 
NIHSS score of 6 or more, ASPECTS of 6 or more and prestroke mRS score 0 to 1.137  
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2.4.4.7 Randomized trials, 2016 
Recently, in the end of august 2016, the results from The THRombectomie des Artères 
CErebrales (THRACE) trial was published.138 This trial was designed in 2009 before the 
results of the IMS III trial became available and had a similar protocol, comparing IVT plus 
thrombectomy to IVT alone. The patients were not selected on image-based criteria, except 
that a large vessel occlusion had to be present. In France, 26 centres included a total of 414 
patients between June 1, 2010 and Feb 22, 2015. The study was halted early (planned for 480 
patients) after an interim analysis showing superiority for the intervention group. Functional 
independence, mRS 0-2, was 53% in the intervention group compared to 42% in the IVT 
alone group, with an OR 1.55, 95% CI 1.05 – 2.30. There were 59 patients (29%) in the 
intervention group that did not have thrombectomy. Time from randomization (performed 
after IVT, and therefore only affecting the group randomized to receive additional 
thrombectomy) to groin puncture was considerably higher than in other trials, which may 
partly explain the reduced difference between the groups compared to the studies published in 
2015.  
Even more recently, in September 2016, the results from The Randomized, Concurrent 
Controlled Trial to Assess the Penumbra System’s Safely and Effectiveness in the Treatment 
of Acute Stroke (THERAPY) was published in Stroke.139 The study was designed to evaluate 
the potential benefit of IVT plus aspiration thrombectomy with the Penumbra System (instead 
of using for example a stent retriever) compared to IVT alone. The study was halted early, 
after inclusion of 108 of 692 planned patients, based on the favourable results from the five 
randomized trials mentioned above. THERAPY did not meet its primary end point, mRS 0-2, 
but it did demonstrate a direction of effect toward benefit. 
 
2.4.5 Special considerations concerning the posterior circulation 
All the randomized trials on thrombectomy that have been described above concern the 
anterior circulation. Anterior circulation stroke is more common, with posterior circulation 
stroke accounting for only about 20% of all ischemic strokes.140 The NIHSS and ASPECTS 
are both designed for anterior circulation stroke, and symptoms from the posterior circulation 
are often more diffuse, including decreased level of consciousness, visual disturbances, 
vertigo and nausea, apart from more obvious symptoms of stroke such as hemiparesis and 
speech impairment. Acute severe brainstem stroke with angiographically proven 
vertebrobasilar artery occlusion has a poor prognosis if untreated, with a mortality rate of at 
least 75%.141 
In 2009, the Basilar Artery International Cooperation Study (BASICS) was published in the 
Lancet.140 It was a prospective registry study concerning treatment and outcomes of acute 
basilar artery occlusion. Both IVT and IAT were analysed, with very poor outcome in both 
groups. Intra-arterial treatment in this study was in the majority of cases treatment by intra-
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arterial thrombolysis alone, but in some cases IAT was combined with mechanical 
thrombectomy and in a minority of cases the treatment was thrombectomy alone. Their 
results did not support unequivocal superiority of IAT over IVT.  
There have been several case series addressing intra-arterial thrombolysis as therapy of 
basilar artery occlusion, many of the larger ones discussed in a systematic analysis by 
Lindsberg et al. 2006, in which the authors concluded that the effect of IVT probably does 
not differ much from the effect of IAT.142 In their analysis of 420 patients (from 3 studies of 
IVT and 10 studies of IAT), 24% of patients treated with IAT and 22% of patients treated 
with IVT reached good outcomes. They also compared patients in whom recanalization had 
occurred to patients without recanalization, in which 38% versus 2% reached good outcome. 
There were 40/76 (53%) deaths in the IVT patients and 190/344 (55%) after IAT.   
Treatment of basilar occlusion with mechanical thrombectomy has shown good results in 
several case series 143-148. In 2015, Gory et al. performed a systematic review of basilar artery 
occlusions treated with stent retrievers.149 The review included sixteen studies, altogether 
showing a good outcome (mRS 0-2) in 42%, with a recanalization rate of 81%, and a 
mortality of 30%.  
 
 
  
  29 
3 AIMS  
The overall aim of this doctoral thesis was to study the outcome and safety of mechanical 
thrombectomy. By analysing the outcome for patients treated at the Karolinska University 
hospital, we aimed to contribute to the knowledge about outcome and safety for this 
technique (Study I, II and III). 
When this doctoral project started, the technique of mechanical thrombectomy was still 
developing and published results were promising, but no large randomized trial had been 
performed. An initial aim was to use data from the Swedish national stroke registry and 
compare patients who were treated medically to patients who underwent mechanical 
thrombectomy at our hospital. In this way we hoped to be able to assess the value of the 
technique without having to perform a randomized study, since we had ethical considerations 
about randomizing patients due to the good local results with mechanical thrombectomy. 
Due to the rapid knowledge development of the field, and especially after the positive results 
from several randomized trials published 2015, we had to partly review our aims: 
Firstly, we performed a meta-analysis of the randomized trials (Study IV). 
Secondly, since the positive results from the randomized trials led to new treatment 
recommendations, which in many way were similar to what had been in practice at our 
hospital during the study period, we used data from the Riksstroke database and from the 
local treatment database in Stockholm to assess the potential demand for mechanical 
thrombectomy if all residents in Sweden were offered treatment according to the new 
recommendations (Study V).  
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4 MATERIAL AND METHODS 
 
4.1 SETTING 
The Department of Neuroradiology at Karolinska University Hospital is the sole provider of 
neuroendovascular treatments in a catchment area of approximately 2 million, and during the 
study period, acute endovascular stroke treatment was provided by initially three and 
eventually four* designated neurointerventionists on a 24/7 basis.  
Study I comprised all patients treated with thrombectomy for acute basilar artery thrombosis 
at the department of neuroradiology, Karolinska University Hospital, Stockholm, from 
September 2005 to November 2010. During the study period, mechanical thrombectomy was 
the preferred treatment for basilar artery occlusion and there were no patients with basilar 
artery occlusion treated with intravenous thrombolysis only.  
In study II, every patient treated with mechanical thrombectomy for acute ischemic stroke 
from September 2005 through December 2011 was included. From the same material we then 
extracted patients with anterior circulation stroke, and these patients were analysed in more 
detail in Study III. The patients with anterior circulation stroke during the years 2009-2011 
were also used as a comparison to patients from the Swedish National Stroke Registry, 
Riksstroke, in study V. 
Study IV was a meta-analysis of six randomized multicentre trials from different parts of the 
world. 
 
4.2 STUDY I-III AND THROMBECTOMY PATIENTS IN STUDY V  
4.2.1 Patient selection 
Patients were either admitted directly to the Karolinska University Hospital or transferred 
from one of six referring hospitals within the region. In addition, patients were occasionally 
sent from more distant hospitals outside the primary catchment area.   
The selection of patients for thrombectomy was based on both clinical and radiological 
parameters. The decision to perform thrombectomy, or not, was taken jointly by the 
neurointerventionist and the stroke neurologist on call, and was dependent on many factors, 
such as areas of already manifest infarction, location of thrombus, tortuosity of vessels, extra 
cranial stenosis or dissection, co-morbidities, time, age and clinical judgement.  
 
                                                
* The author of this thesis. 
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4.2.1.1 Clinical selection 
In the anterior circulation, patients with NIHSS scores of 8-30 (scores changed to 6-25 in 
2010) without severe comorbidities were eligible for thrombectomy. Exceptions were made 
for some patients with an NIHSS score less than 6 when symptoms included aphasia. If there 
were no contraindications, all eligible patients were treated with intravenous thrombolysis 
(IVT). 
There was no clear definition of severe comorbidity, rather was it up to the neurologist on call 
together with the neurointerventionist to decide. Generally severe heart failure, advanced 
dementia, terminal cancer and other major diseases were regarded as a contraindication to 
thrombectomy. Many diseases adding up together could also be considered as a 
contraindication.  
Age was not considered to be a limit, but in patients above 80 years of age special care was 
taken to evaluate the potential for rehabilitation. 
Time from onset of stroke symptoms was not a definite criterion; we tried to rely more on 
radiological appearance than on time from stroke onset. As a rule of thumb we were reluctant 
to treat patients with anterior circulation stroke later than 8 hours, and patients with posterior 
circulation stroke later than 16 hours after onset. Of course, we preferred to treat patients as 
quickly as possible, and took great care in minimizing the time from arrival to hospital to 
groin puncture – an especially difficult task if patients needed to be transferred between 
hospitals. 
In posterior circulation stroke it can be very difficult to predict which patients would benefit 
from thrombectomy, since even unconscious patients may recover well. We regarded 
fluctuating symptoms as a good sign. When study I was performed, the NIHSS score was not 
systematically registered for this patient category, but GCS was. Patients in study I did not 
receive IVT. 
 
4.2.1.2 Radiologic selection 
Patients were evaluated with non-enhanced CT, which was complemented with CT perfusion 
(CTP) and CT angiography as soon as a hemorrhage had been excluded. Based on imaging, 
mechanical thrombectomy was considered for all patients with remaining symptoms, large-
vessel occlusion and with salvageable brain tissue as interpreted from the CT, CTP, and CT 
angiography. The role of CTP in the workup was to assess if there were areas of tissue with 
normal or next to normal blood volume in areas with restricted perfusion, i.e. that there would 
be viable tissue (penumbra) to save with revascularization. There were no formal limits on 
CTP that hindered treatment; rather CTP was regarded as one piece of a puzzle together with 
the other factors describe here. In case of severe renal failure, CTP was not performed. 
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MRI was mostly used in cases of unconscious patients with posterior circulation stroke, in 
which we wanted to evaluate the extent of manifest infarction in the brainstem and 
cerebellum. 
 
4.2.2 Procedure 
Study I (basilar occlusion) included patients from 2005-2010, during the first years of which 
different variants of the Merci Retriever were used. In the spring of 2009 we started to use 
stent-retrievers and from summer 2009 we almost exclusively used stent-retrievers. The 
device was usually delivered through a 6 French (F)* Envoy catheter, but depending on the 
size of the vertebral artery and of the choice of the operator, sometime a 7 or 8 F guide 
catheter was used instead. Study II and III includes patients from 2005-2011 and study V 
includes patients only from the years 2009-2011 and therefore a relatively higher number of 
stent-retrievers was used. In the anterior circulation strokes, most often a long 8 F Arrow 
introducer sheet was placed in the common carotid artery, followed by an 8 F Merci balloon 
guide catheter in the internal carotid artery. After confirming the presence of the 
thromboembolus on an angiogram, a microcatheter was advanced through the thrombus with 
the aid of a microguidewire. After release of the stent retriever, centred at the obstructive 
blood clot, it was left in place for approximately 5 min (3–10) before the actual 
thrombectomy was performed. The balloon was inflated with simultaneous aspiration in the 
guide catheter to create flow reversal in the internal carotid artery (ICA) during the 
thrombectomy. For early cases in the series, where the Merci device was used, the device was 
positioned distal to the thromboembolus. In the vertebral arteries no balloon guide catheter 
was used. 
For patients with so-called tandem occlusions in the anterior circulation, an occlusion in the 
proximal ICA due to acute dissection or atherosclerosis in addition to a distal ICA or middle 
cerebral artery (MCA) occlusion, the procedure was modified to include angioplasty or 
carotid stenting. Placement of a stent, either extra- or intracranial, was, however, avoided 
when possible due to the need for anti-platelet aggregation therapy, which in the context of a 
potential acute ischemic infarct was considered to impose a risk for a severe reperfusion 
hemorrhage.  
As a supplement to thrombectomy for treating small distal emboli, alteplase was sometimes 
infused intra-arterially in combination with careful microcatheter and microguidewire 
manipulations.  
 
                                                
* 1 French is exactly 1/3 millimeter. 
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Figure 18.  Frontal view, showing the tip of the guide catheter placed in the left internal 
carotid artery from which the microcatheter extends to the stent retriever, which is in position 
over the thrombus (not seen) in the middle cerebral artery. 
 
 
4.3 BASELINE AND OUTCOME PARAMETERS 
For study I-III and partly V, baseline and outcome data were retrieved from computerized 
records at the hospital. ASPECTS and mTICI scores were assessed. Time from onset of 
stroke symptoms to groin puncture was noted. Patients who went to sleep with normal status 
and woke-up with stroke symptoms were classified as “wake-up” strokes. This group could 
also include some patients found with stroke symptoms and unknown time of onset (no 
known “last seen well”-time). In study IV (the meta-analysis) data were received from the 
already published randomized trials. Data of stroke patients from all of Sweden for study V 
was given from Riksstroke, the Swedish National Stroke Register. 
 
4.3.1 Pre intervention 
GCS (study I only), NIHSS score and ASPECTS were used to assess stroke severity. GCS 
and NIHSS scores were considered in the acute setting, whereas no scoring scale was used to 
Stent retriever, over the 
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Microcatheter 
 
 
 
 
Guide catheter 
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evaluate the unenhanced CT acutely; the scoring according to ASPECTS was performed 
retrospectively. Sex and age were noted. Different aspects of time were studied in the 
different studies (I-III); time from onset to arrival to the Karolinska University Hospital, time 
from onset to groin puncture or from groin puncture to first revascularization. 
 
4.3.2 Post intervention 
The use of stent retriever or older devices was noted in study II. Revascularization was 
assessed using mTICI. A post-procedure mTICI score of 2b or 3 was considered to represent 
a successful revascularization. Severe adverse events were noted, most interesting being the 
presence of symptomatic hemorrhage (according to SITS-MOST-definition).54 NIHSS score 
was of course also of great importance after the procedure, and was compared to the pre-
interventional score. ASPECTS was also noted on follow-up CT, and compared to the pre-
interventional score. 
 
4.3.3 Long-term follow-up 
The primary outcome measurement in all of the studies was modified Rankin Scale (mRS) 
score at 3 months, with functional independence (mRS 0-2) regarded as a good outcome. 
Mortality equals mRS 6. 
 
4.4 META-ANALYSIS (STUDY IV) 
Only complete, randomized controlled trials published in their entirety were considered for 
inclusion. The intervention group was endovascular treatment in addition to IVT, the control 
group was IVT, and at least two-thirds of all participants had to have received IVT. PubMed, 
the Cochrane Central Register of Controlled Trials, and the National Institutes of Health 
Clinical Trials were searched from the date of inception until 17 April 2015.  
The primary specified outcome was the proportion of patients with mRS score 0–2 at 90 days 
from stroke onset. Secondary outcomes included mRS score 0–1 at 90 days, mRS score 0–3 
at 90 days, mortality at 90 days, intracerebral hemorrhage within 90 days, and mRS score 5–6 
at 90 days. To maintain high homogeneity between the included trials, the subgroup of 
patients from the IMS-III trial that did not have vessel occlusion on imaging were excluded 
from further analysis. 
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4.5 RIKSSTROKE (STUDY V) 
The National Stroke Registry in Sweden, Riksstroke, intends to register all patients with acute 
stroke treated in Sweden, the coverage calculated to be 85-95% during the study period 
(2009-2011). The number of thrombectomies began to be registered in 2009. From 
Riksstroke we collected information on patients from all of Sweden for the time period 
corresponding to our database. Patients with an anterior circulation stroke, who arrived 
primarily (without any pre-hospital triage) to Karolinska University Hospital, Solna, 2009-
2011 and were treated by thrombectomy, were analyzed and compared to the total number of 
patients treated for ischemic stroke at Karolinska. We assumed that the proportion of 
performed thrombectomies among the unselected patients arriving primarily to our hospital, 
divided in specified intervals on the NIHSS (0-5, 6-11, 12-19 and 20-25), would represent the 
proportion of patients potentially eligible for thrombectomy if other hospitals followed the 
same practice. By using data from the most recent available annual report from Riksstroke, 
we estimated the number of stroke cases in each defined NIHSS category and compared it to 
the proportion of performed thrombectomies at Karolinska, in order to estimate the potential 
number of thrombectomies in Sweden if all hospitals selected patients according to the new 
guidelines published in 2015 and 2016.136,137 
 
4.6 STATISTICS 
4.6.1 Study I-III and V 
For the statistical analysis, we used SAS statistical software (V.9.1; SAS Institute Inc.). 
Ninety-five percent confidence intervals (95 % CI) were calculated assuming a binomial 
distribution. For testing independence between outcome and exposure variables, we used 
Pearson’s exact chi-squared tests. Observations with missing values were excluded. A p-
value of <0.05 was considered statistically significant.  
Since a delayed assessment of mRS score may lead to an overestimation of patients with 
good outcome, we assessed the potential impact of the delayed mRS assessments by doing 
sensitivity analyses where an extra point was added to the mRS score for all patients who 
were assessed after more than 6 months (study I and II).  
Tests for trends and multivariate regression analyses were done by analysing categories as 
continuous variables in logistic regression using the PROC LOGISTIC statement in SAS 
(study III).  
The studies were approved by the research ethics committee at Karolinska Institutet.  
 
4.6.2 Study IV (meta-analysis) 
Two independent reviewers performed the statistical analyses using Review Manager 
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(RevMan, V.5.3., Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014). Review Manager was used for data presentation. Data were pooled in the intervention 
group and the control group. Outcome heterogeneity was evaluated with Cochrane’s Q test 
(significance level cut-off value at <0.10) and I2 (significance cut-off value >50%). A p-value  
of <0.05 was considered statistically significant. The Mantel–Haenszel method was used for 
dichotomous outcomes with fixed effect or random effect (DerSimonian and Laird)150 where 
appropriate, according to outcome heterogeneity. Odds Ratio (OR) with 95% CI were 
calculated for all outcomes.  
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5 RESULTS 
 
5.1 STUDY I-III 
5.1.1 Baseline data 
In study I, we included 28 patients with acute basilar artery occlusion, 8 women and 20 men. 
At admission, 14 of 28 had GCS of 8 or less. The number of pre-procedure acute infarcts was 
4 out of 8 (50%) women and 2 out of 20 (10%) men (p=0.038). Treatment was initiated 
within 6 hours from stroke onset in 19 patients. 
In study II, we included 240 patients, and of these 192 (80%) had an anterior circulation 
stroke. There were 138 (57.5%) men and 102 (42.5%) women. Of all patients, there were 
45% under the age of 65, 46% between 65 and 79 years of age, and 9% were 80 years or 
older. The median NIHSS score, all patients included, was 16. In patients with anterior 
circulation stroke the figure was the same, but for patients with posterior circulation stroke 
the median NIHSS score was 11. IVT before the endovascular intervention was administered 
to 96 patients (40%). Baseline mRS, reflecting the functional status of the patient before 
stroke onset, was 1 or more in 18%. 
Among the 192 patients with anterior circulation stroke (the material also used in study III 
and patients from 2009-2011 in study V) there were 104 (54%) men and 88 (46%) women, 
with a mean age of 64.1 years and a median age of 66 years. The distribution by age was 
basically the same as for the complete material. The median ASPECTS was 8. Pre-
intervention IVT was given to 89 patients (46%), and of these patients 44% were women. In 
84% of the cases the functional status before the current stroke was excellent (baseline mRS 
score 0), and in 16% the mRS score was 1 or more. In 71% of the cases, stent retrievers were 
used, and in 15%, a non-stent retriever was utilized (mostly the Merci Retriever, in a few 
cases the Amplatz GooseNeck Microsnare). In 4% of the cases, a combination of stent 
retriever and non-stent retriever was used. In 7% of the cases, no retriever at all was used, but 
instead mechanical manipulation and intra-arterial thrombolysis were performed.  
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Table 1. Study II: Patient characteristics by thrombus location and pre-intervention IVT.151 
The patients with anterior circulation stroke were also included in study III. 
 
 
5.1.2 Angiographic results 
In study I (basilar artery) 64% of patients had a successful recanalization (mTICI score 2b or 
3), and in study II (both anterior and posterior circulation, including the patients studied in 
study I) 72% had a successful recanalization. If only stent retrievers were used (study II) the 
rate of mTICI score 2b and 3 were 80%, to compare with 66% if only non-stent retrievers 
were used (mostly the Merci Retriever). Even when only anterior circulation stroke was 
accounted the rate of successful recanalization was 72%. 
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Figure 19. Study II: mTICI score post-thrombectomy, total (237 patients), stent retrievers 
(151 patients), and non-stent retrievers (mainly Merci) (47 patients).  
 
 
 
5.1.3 Clinical results 
In study I, the overall proportion of patients with a favourable outcome (mRS 0-2) was 57% 
(95% CI 37%-75%). There were six deaths (21%, 95% CI 8% to 41%) in the cohort. There 
was a strong negative association between outcome and CT detectable pre-procedure 
infarction (p=0.002). Among patients without signs of acute infarction on non-enhanced CT 
scan prior to treatment, the proportion with a favourable outcome was 73% (95% CI 50% to 
89%). The proportion of deaths in this cohort was 9% (95% CI 1% to 29%). None of the 
patients with signs of acute infarction prior to treatment had a favourable outcome. 
In study II, 50% (120/240) of all patients reached a good functional outcome (mRS 0–2). In 
the subgroup of patients with an anterior circulation stroke the proportion was almost 
identical (49%, 95/192). Patients that had received IVT before the intervention had a good 
functional outcome in 47% (42/89), compared to 51% (53/103) of patients that did not 
receive IVT.  For patients with no functional deficit prior to stroke onset (mRS score 0 prior 
to stroke onset), the proportion with good functional outcome was 54%. In patients with an 
anterior circulation stroke the median NIHSS score was 16 prior to thrombectomy and 7 
afterwards, thus a reduction of 9 points. The median ASPECTS was 8 prior to treatment and 
7 afterwards. At three months, 13.5% of patients with stroke in the anterior circulation were 
deceased (mRS 6), for both anterior and posterior circulation stroke cases the same figure was 
14.5%. When stent retrievers were used recanalization and a good functional outcome was 
achieved more often than with non-stent retrievers, although not statistically significant 
(figure 19 and 20). 
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Figure 20. Study II: mRS score 3 months post-thrombectomy, total (237 patients), stent 
retrievers (151 patients), and non-stent retrievers (mainly Merci) (47 patients).  
 
 
In study III, we found a statistically significant association between age and good functional 
outcome in unadjusted analysis. Patients younger than 50 years of age achieved a mRS score 
of 0-2 in 79%, compared to 39% of the patients older than 80 years of age. For patients 
without prior functional deficits (mRS score 0 before stroke onset), the difference was less 
(81% compared to 54%) but still significant. Patients aged 50-64 achieved mRS 0-2 in 47% 
and those aged 65-79 in 44% (50% and 49% respectively, if mRS 0 before stroke). As 
expected, there was an association between pre-thrombectomy NIHSS score and mRS score 
at 3 months (P = 0.0001). We also found an association between pre-thrombectomy 
ASPECTS and mRS score, although the latter was not statistically significant (P = 0.064). 
There was no statistical association found between time from symptom onset to groin 
puncture and functional outcome, but this analysis also included patients with wake-up 
stroke. A statistically significant association was found between grade of recanalization 
(mTICI post) and improvement in NIHSS score as well as with functional outcome. There 
was no suggestion of poorer outcome for patients older than 80 years of age, compared to 
those aged 50-64 or 65-79, when both pre-treatment infarct size, pre-treatment NIHSS score, 
time to treatment, and age were included in a multivariate regression analysis, but in the 
oldest age category only 1 patient was included with ASPECTS 6-7 and no patient with 
ASPECTS 0-5 (table 2). We found that in elderly patients we had had a tendency to select 
patient with higher ASPECTS than in younger patients. Interestingly, patients younger than 
50 years of age did significantly better, even though 69% of patients in this age group had an 
ASPECTS ≤ 7.   
There were 22 patients with wake-up stroke in study III, of which 14 (63.6%) patients had a 
reduction in the NIHSS score of 4 or more points and 10 (45.5%) patients were functionally 
independent (mRS 0-2) at 3 months. In the group of patients with wake-up stroke and with no 
functional deficit (mRS 0) before the stroke, 9 of 17 patients (52.9%) were functionally 
independent at 3 months. In a multivariate regression analysis, there was no indication of 
poorer outcome for patients with wake-up stroke. 
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  Odds Ratio Estimates [95% CI] 
      
Sex Male 0.76  [0.36, 1.59] 
  Female   
  
 
  
 Age 16-49 4.61  [1.34, 15.9] 
  50-64 1 [ref] 
  65-79 0.64  [0.27, 1.52] 
  80-91 0.80  [0.18, 3.62] 
  
 
  
NIHSS pre-
thrombectomy 
0-11 1 [ref] 
12-19 0.34  [0.13, 0.89] 
20-35 0.22  [0.07, 0.69] 
  
 
  
ASPECTS pre 0-5 0.25  [0.06, 0.99] 
  6-7 0.29  [0.08, 1.01] 
  8-9 0.54  [0.17, 1.69] 
  10 1 [ref] 
  
 
  
Time to groin 
puncture 
Within 3 h 1 [ref] 
3 – 4.5 h 1.60  [0.43, 5.94] 
More than 4.5 h 0.87  [0.24, 3.17] 
In hospital 0.84  [0.18, 3.90] 
Wake up 0.63  [0.13, 3.19] 
 
Table 2: Study III: Multivariate regression analysis. Test for good functional outcome, when 
pre-thrombectomy mRS=0 
 
 
5.1.4 Severe adverse events 
In study II, we found that 8 patients (4.2%), all of who had an occlusion in the anterior 
circulation, suffered from a symptomatic intracerebral hemorrhage (SICH) according to the 
SITS-MOST definition. These hemorrhages were located in the infarcted territory (so-called 
reperfusion hematomas), most of which occurred within a few hours after the procedure. In 
addition, 3 hemorrhages occurred during the intervention, resulting in a total proportion of 
SICH of 5.7% in the anterior circulation (4.6% in total). In this study, no SICH was seen in 
patients above the age of 80 years, and we found no significant associations between the 
incidence of SICH and sex, age, baseline mRS, pre-interventional NIHSS and ASPECT 
scores, or time between symptom onset and treatment. The incidence of SICH was lower 
when stent retrievers were used, compared with non-stent retrievers (mostly the Merci 
retriever), but the difference was not statistically significant (figure 21). In study III, we found 
a stepwise increase in risk of SICH with increasing pre-treatment infarct size (measured in 
ASPECTS), but this increase was not statistically significant. Out of 6 patients with a post-
thrombectomy mTICI score of 1, two had a SICH and the P value for heterogeneity was 
0.047.  
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Figure 21. Study II: Symptomatic intracranial hemorrhage (SICH) post-thrombectomy, 
total (237 patients), stent retrievers (151 patients), and non-stent retrievers (mainly Merci) 
(47 patients).  
 
 
5.2 STUDY IV  
A total of 2 138 publications were identified; of those 1 942 publications did not match the 
eligibility criteria. Out of the remaining 196 abstracts eligible for evaluation, 22 publications 
were selected for full text evaluation. Of the 22 publications analysed in full text, 11 were not 
randomized control trials and hence were excluded. Five randomized trials were further 
excluded since they did not meet the inclusion criteria, in one study (by Miao et al) no 
patients received IVT,152 in MR RESCUE less than 50% received IVT,114 in SYNTHESIS no 
patients in the intervention group received IVT,116 and in  SWIFT and TREVO 2 intervention 
with two different devices were compared without any control group receiving IVT.112,113 
The remaining 6 articles met all of the eligibility criteria and were included in the meta-
analysis (IMS III, MR CLEAN, ESCAPE, EXTEND-IA, SWIFT-PRIME and 
REVASCAT).115,125-129 In total, the 6 trials randomized 1943 patients to either the 
intervention group (55%) or the control group (45%).  
Time from symptom onset to inclusion varied between less than 3 h in the IMS-III trial to less 
than12 h in the ESCAPE-trial. In all trials both the control group and the intervention group 
received IV tPA, if eligible. Time from symptom onset to treatment with IVT varied from 
less than 3 h in IMS-III to less than 4.5 h in the other trials. Median or mean age varied 
between 65-71 years of age. Median NIHSS score was 13–18. Imaging of vessel occlusion 
status was required before inclusion in all trials, except the IMS-III trial. In the IMS-III trial, 
284 patients were randomized before CT angiography was allowed in the study. We therefore 
chose to perform a post hoc analysis including only patients with baseline CT angiography 
and vessel occlusion from the IMS-III trial.153 Finally, in total 824 patients were included in 
the intervention group. 
The primary outcome measure, mRS score of 0–2 at 90 days from symptom onset, was 
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favoured in the intervention group. The proportion of patients with mRS score 0–2 after 90 
days was 46% in the intervention group and 28% in the control group. The absolute risk 
reduction for the intervention group compared to the control group was 19% (95% CI 14% to 
23%). Number needed to treat (NNT) for mRS 0–2 in the intervention group was 6 (95% CI 
4 to 7). There was a significantly reduced risk of mortality in the intervention group (15%) 
compared with the control group (20%), with an absolute risk reduction for death of 4% (95% 
CI 1% to 8%) in the intervention group. Patients receiving IVT alone had a higher probability 
of mRS 5–6 and death after 3 months; this has not been shown in previous single randomized 
trials. For mortality alone, the risk reduction was not significant in the second analysis, when 
the results from IMS III trial were excluded (table 3 and 4). 
 
 
 
Table 3. Study IV: Outcome 90 days after stroke symptom onset comparing the intervention 
and control groups (from IMS III, the subgroup with CT angiography verified vessel 
occlusion).  
 
 
Table 4. Study IV: The same outcomes as Table 3, but with the results from the IMS III trial 
excluded. 
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5.3 STUDY V 
During the time period for our computerized database (2009-2011), Riksstroke reported      
75 890 stroke treatments for all of Sweden, and of these 65 378 were ischemic stroke. In the 
ischemic stroke population, 24 125 patients had an NIHSS score registered. After exclusion 
of patients reported from the Karolinska University Hospital-Solna (since they might have 
been triaged because of stroke severity) and a few for other reasons, 23 021 patients were 
included in our study. Among patients arriving primarily (without any pre-hospital triage) to 
Karolinska, thrombectomy was performed in 6.5% of all stroke-cases, which was 9 times 
higher than in all of Sweden (0.72%). 
At the study time, the most recent Riksstroke data was the annual report from 2013. There the 
total number of ischemic stroke events was 20 961, and 232 thrombectomies were recorded. 
The estimated number of potential thrombectomies among these ischemic stroke patients was 
1 269, assuming that the NIHSS score distribution was the same as in our material. If the new 
guidelines for acute ischemic stroke, as executed at Karolinska, had been implemented in all 
of Sweden, 1 037 (1 269-232) additional thrombectomies would potentially have been carried 
out. The number of thrombectomies would have been more than 5 times higher (1 269/232). 
 
5.4 SUMMARY 
To summarize we have found that, in study I, thrombectomy had significant better result 
compared with other studies on posterior circulation stroke when either IVT or no reperfusion 
therapy at all was given. Study II showed that mechanical thrombectomy was a safe and 
effective method to restore blood flow in selected patients suffering from an acute ischemic 
stroke, and that stent retrievers were more effective in revascularisation than older devices 
(although not statistically significant in this study). We also found that neither prior treatment 
with IVT nor high-attained age was significantly associated with risk of symptomatic 
intracranial hemorrhage. In study III we found that when selecting patients according to our 
practice, functional outcome after mechanical thrombectomy was as good for those over 80 
years of age as for those between 50-64 or 65-79 years of age. In study III, we found no 
indication of poorer outcome for patients with wake-up stroke. In the meta-analysis, study IV, 
we found that endovascular treatment combined with IVT led to a higher ratio of patients 
with an improved clinical outcome than treatment with IVT alone, with an absolute risk 
reduction of 19% for the intervention group compared with the control group. An estimation 
of future need for thrombectomy in study V, revealed that the rate of thrombectomies in 2013 
might have been more than five times higher in Sweden than the actual rate if the new 
treatment recommendations had been implemented by then.  
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6 DISCUSSION 
 
6.1 GENERAL CONSIDERATIONS 
When this project started, endovascular mechanical thrombectomy clearly had promising 
results in published registries and studies, but there were no large, multicentre, prospective 
randomized trial comparing mechanical thrombectomy with best medical treatment. As with 
every other interventional procedure, mechanical thrombectomy obviously also carries a risk 
for the patient and the question of risk-benefit becomes evident. Because of this, many voices 
argued for large randomized trials. Others, however, claimed that with the excellent results 
that were reported for mechanical thrombectomy in properly selected patients, it would 
indeed be unethical to deny stroke patients this opportunity and thus there was no need for a 
randomized study.  
Our way to address this dilemma was an observational study of our own material. We also 
planned to compare stroke patients who had been treated with thrombectomy to patients who 
had either IVT alone or no recanalization therapy. There have been studies comparing results 
from well-designed observational studies, including control subjects, with randomised 
controlled trials of the same topic, indicating that the results are remarkably similar 
independent of study design.154 When the results from the randomized trials published in the 
beginning of 2015 were overwhelmingly positive, and confirmed our early study results, we 
decided to instead conduct a study to estimate the future need of thrombectomies (study V).   
The main limitations with the studies included in this thesis are listed below. Study I-III and 
V (thrombectomy patients) emanate from a single centre, limiting the possibility to generalize 
the results. Since the studies were not randomized, there are no reference groups treated with 
best medical care for comparison. The retrospective design with data collected from medical 
records or registry data made us dependent on the information available in the records, and 
therefore there are some missing data. We also lack information on patients who we decided 
not to treat with thrombectomy. The study I cohort is small, limiting the ability for subgroup 
analysis. In study V there is a difficulty in assessing how many potential thrombectomy 
candidates would develop a large infarction during transportation to a tertiary centre, thereby 
disqualifying them from the procedure. Finally, the observational design of the studies is 
subject to all limitations inherent with this methodology. 
Being a single centre study, the presented work also has some advantages, such as access to 
updated medical records for all patients and a consistency of patient selection and basic 
treatment techniques. All consecutive thrombectomies performed were included, providing us 
with useful data of what can be expected outside of a randomized trial. Patients who would 
have been included in a randomized study are to a large extent included in our material. All 
patients were included on the basis of radiological verified vessel occlusion, and the use of 
CTP for patient selection allowed us to also include patients with wake-up stroke. In study V 
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the availability of data from Riksstroke gave us access to information from a large number of 
stroke patients from all over Sweden. 
 
6.2 STUDY I – POSTERIOR CIRCULATION STROKE  
In study I, we found that with mechanical thrombectomy as the first line treatment for acute 
basilar occlusion, the proportion of patients who gained functional independence was 57% 
and for patients without signs of acute infarction before thrombectomy the proportion was 
73%. Only 21% died, and among those patients without CT detectable infarcts before 
treatment, mortality was only 9%. 
In a previous meta-analysis of intravenous thrombolysis for basilar artery occlusion a 
favourable outcome (mRS 0-2) for only 22% was reported, compared with 57% in our 
study.142 Mortality was 53% (40 - 70%) for cohorts treated with IVT. The corresponding 
values for intra-arterial thrombolysis were not superior. In BASICS (a prospective registry 
study published in Lancet Neurology in 2009), the largest study presented on the treatment of 
basilar artery occlusion, only 34% of the patients (41 of 121 patients) treated with IVT had a 
favourable outcome (mRS 2 or less) and 34% of the patients died (41 patients).140   
Another meta-analysis of reperfusion versus no reperfusion of acute basilar occlusion, 
including 45 observational studies (n=2056), showed NNT of 3 to decrease death and 
dependency (defined as mRS >3) and NNT of 2.5 to decrease death alone.155 In this meta-
analysis recanalization achieved with IVT, IAT or thrombectomy were not separated. 
There have been several single centre studies published during the last years with good 
functional outcomes following basilar artery thrombectomy.143-148 A systematic review of 16 
studies, in which basilar artery occlusions were treated with stent retrievers showed a good 
outcome (mRS 0-2) in 42%, with a recanalization rate of 81%, and a mortality rate of 30%.149  
The results from study I, supported also by other studies on thrombectomy for basilar artery 
occlusion, strongly indicate that mechanical thrombectomy is at least as effective in the 
posterior circulation as in the anterior circulation.  
Recruitment is on-going for Basilar Artery International Cooperation Study (BASICS), a 
randomized trial comparing intra-arterial treatment in addition to best medical management 
(BMM) with BMM alone (BMM may include IVT). With support of the positive result from 
randomized trials of anterior circulation stroke, together with the results from our and other 
single centre studies, ethical considerations raise concerns against randomising patients with 
basilar occlusion and thereby potentially denying them thrombectomy. An observational 
study or a registry study could be a more appealing alternative. 
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6.3 STUDY II – REVASCULARIZATION, OUTCOME AND SAFETY 
In study II we found that by treating acute occlusions in the large cerebral arteries with 
mechanical thrombectomy, 50% of all patients obtained independence (mRS 0–2) at follow-
up. When restricting the analysis to patients with excellent functional status before stroke 
onset 54% had gained independence. In our study, performed with a mixture of old and new 
devices, we achieved TICI 2b-3 in 72% of all cases, but when we used only stent retrievers, 
mTICI 2b-3 was achieved in 80% compared to 66% when non-stent retrievers were used (no 
statistically significant difference). We demonstrated that neither prior treatment with IVT 
nor high-attained age was significantly associated with risk for symptomatic intracranial 
hemorrhage. 
At the time (April 2014) of publication of the results of study II, our study confirmed the 
results from a retrospective multicentre study by Davalos et al., using the Solitaire device,111 
as well as from the SWIFT-trial 111  and TREVO EU.110 In study II, the proportion of patients 
with functional independence three months after stroke was higher in our cohort than in the 
intervention groups in the three randomized trials, IMS III, MR RESCUE and SYNTHESIS, 
published in 2013.114-116 
When the five randomized trials were published in 2015, their results were in line with the 
results presented in study II.125-129 The proportion reaching independence three month after 
thrombectomy varied from 33% to 71% (Table 5). In the control groups (IVT) the proportion 
varied from 19% to 40%. In our meta-analysis, study IV, mRS 0-2 was reached in 46% in the 
intervention group and in 28% in the control group. Recanalization (mTICI 2b-3) was 
achieved in 59% to 88%. Mortality (mRS 6 or death at 3 months) varied in the intervention 
group from 9 to 18%, compared to 15% in our meta-analysis. In the control group it varied 
from 8 to 20%.  
Although all of these studies are consistent, there are obviously differences in the degree of 
revascularization as well as good functional outcome at three months. The two trials with the 
best results are EXTEND-IA and SWIFT-PRIME,127,128 both of which had shorter time from 
stroke onset to thrombectomy than the other trials, and also used penumbral imaging for 
selection. ESCAPE,126 which had intermediate results, used multiphase CT for collateral 
imaging for selection. MR CLEAN and REVASCAT had longer times from onset to 
intervention,125,129 and used no penumbral or collateral imaging for selection.  
The development of new strategies in health care, such as more awareness of the possibilities 
of performing thrombectomy in acute stroke, increased achievability of rapid referral between 
hospitals and shorter in-hospital door-to-treatment times, together with the development of 
stent retrievers has increased the chances of good functional outcome. The differences in 
revascularisation, good functional outcome and proportion of SICH, although not statistically 
significant, demonstrated between stent retrievers and old devices in study II, can be seen as a 
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function of this development; also reflected in the superior results of later randomized trials 
compared to the inconclusive ones from 2013.  
 
 
  
Study II and 
III 
anterior 
circulation  
MR 
CLEAN 
REVASCAT Escape EXTEND-
IA 
SWIFT 
PRIME 
Study IV  
meta-
analysis 
Number 192 233 
(267) 
103 (103) 165 (150) 35 (35) 98 (98) 824 
Median age 66 66 (66) 66 (67) 71 (70) 69 (70) 66 (65) 65-71 
Median NIHSS 16 17 (18) 17 (17) 16 (17) 17 (13) 17 (17) 13-18 
Median ASPECTS 8 9 (9) 7 (8) 9 (9) - 9 (9) - 
        
TICI 2b-3 [%] 72 59 66 72 86 88 - 
mRS 0-2 at 3 months 
(%) (%) ((%)(%) 
50 33 (19) 44 (28) 53 (29) 71 (40) 60 (35) 46 (28) 
Mortality [%] 14 9 (8) 18 (16) 10 (19) 
((19)(19.0) 
9 (20) 9 (12) 15 (20) 
 
 
Table 5. Baseline characteristics and outcome of patients with anterior circulation stroke 
from Study II and III compared with the five randomised trials and with Study IV (meta-
analysis). Numbers refer to intervention group, with control group in parenthesis, and are 
rounded up or down to the nearest integer. 
 
 
6.4 STUDY III – WAKE-UP STROKES AND ELDERLY 
In study III, we studied patients with anterior circulation stroke in more detail. The most 
interesting results were that both patients over 80 years of age as well as patients with wake-
up stroke, may experience a favorable outcome after treatment - at least if they were selected 
according to the presented local Karolinska practice. 
In Sweden, patients above the age of 80 years have since 2014 been receiving intravenous 
thrombolysis according to new guidelines.156 In many centres they are also considered for 
thrombectomy, even though they were excluded from some of the randomized trials. The 
median age in the five randomized trials published 2015 was between 65-71 years. In all 
those trials patients had to be 18 years old or older. Some of the trials had an upper age limit 
(80-85) but two of them, MR CLEAN and ESCAPE, did not. We found that when patients 
were selected according to local Karolinska practice, there were no significant differences in 
functional outcome after mechanical thrombectomy for those over 80 years of age compared 
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to those aged 50-64 and 65-79 years. This result is supported also by the results from MR 
CLEAN and ESCAPE, where treatment effect was also found to remain consistent over the 
age of 80.   
 
 
Figure 22. Pre and post thrombectomy images of a 90 year old woman who had a NIHSS 
score 21 at arrival. Left M1 occlusion (left image) was found. Thrombectomy was performed, 
and the blood supply restored (right image). Her NIHSS score was 0 when she left the 
hospital. 
 
Time to treatment is of course of great importance for the stroke population in general, even 
though such factors as extent of collaterals may be as important. Since collateral status and 
the remaining function on cellular level is impossible to fully ascertain in advance, we must 
make every minute count in our effort to save brain tissue. The median time from stroke onset 
to groin puncture varied among the randomized trials from 210-269 min (perhaps less in 
ESCAPE, not clearly stated), but the inclusion criteria varied even more; in most cases 
endovascular treatment should be initiated within 6 hours or patients should treated within 8 
hours, but in ESCAPE treatment was to be initiated as late as up to 12 hours after stroke 
onset. 
In study III, we found no statistically significant association between time from symptom 
onset to groin puncture and functional outcome, suggesting that using perfusion imaging as a 
part of the selection process might increase the ability to find the patients most likely to 
benefit from the treatment - even when a long or unknown time has passed between stroke 
onset and initiation of treatment. Another explanation might be that at least some patients 
wake up the moment the stroke occurs, implying that the time actually is not “unknown”.157 
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A recent systematic review concluded that there is not sufficient evidence to make 
recommendations on treatment for patients with wake-up stroke.158 Wake-up strokes were not 
included in any of the randomized thrombectomy trials discussed in this thesis, although 
patients were allowed to start treatment up to 12 hours after stroke onset in ESCAPE, which 
could allow some patients with wake-up stroke to be included even though not clearly 
indicated as such. We found that wake up-strokes, and other causes of unknown time from 
stroke-onset, are a subgroup of patients that would most likely benefit from rapid radiological 
evaluation for eligibility for thrombectomy. The findings highlight the importance of further 
studies for this group of patients, and suggest that future studies on mechanical 
thrombectomy should also include patients with wake-up stroke.  
Encouragingly, there is currently one ongoing study concerning thrombectomy in wake-up 
stroke, Trevo and Medical Management Versus Medical management Alone in Wake Up and 
Late Presenting Strokes (DAWN), still recruiting patients.159 In both Europe and Japan, 
studies involving IVT and wake-up stroke are ongoing.160,161 
 
6.5 STUDY IV – META-ANALYSIS 
The aim of this meta-analysis was to evaluate the role of endovascular treatment in acute 
ischemic stroke. The study included six randomized controlled trials. The results showed that 
endovascular treatment, including mechanical thrombectomy, leads to a higher proportion of 
patients with an improved clinical outcome after 3 months from stroke onset compared with 
the control group receiving IVT alone. Patients receiving IVT alone had a higher probability 
of mRS 5–6 at 3 months, which has not been shown in previous single randomized trials.  
Since our study was published, other meta-analyses have confirmed the conclusion that 
treatment with thrombectomy is associated with better functional outcome than IVT alone, 
although with variable rates depending on included studies.132-135 In April 2016, the Highly 
Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials (HERMES) 
collaboration published a meta-analysis consisting of individual patient data from the five 
randomized trials published 2015.162 The number needed to treat with endovascular 
thrombectomy to reduce disability by at least one level on mRS for one patient was 2.6. With 
individual patient data, subgroup analysis could be made, showing that the results were valid 
also for patients aged 80 years or older, for those randomized more than 300 minutes after 
symptom onset, and for those not eligible for IVT.162 These results also confirm the results 
from study II (patients not receiving IVT) and study III (patients above 80 years of age). 
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6.6 STUDY V – ESTIMATION OF INCREASING DEMAND 
In study V, by comparing our results to patients from Riksstroke, we showed that the number 
of thrombectomies in 2013 might have been more than five times higher than the actual 
number if the practice used at the Karolinska University Hospital – a practice similar to the 
new guidelines - had been extrapolated to all of Sweden. The estimated potential demand for 
thrombectomies was more than 1200 patients compared to the 232 reported that year. 
Although it is difficult to assess how many potential thrombectomy candidates would develop 
a large infarct during transportation to a tertiary center, the study still shows that there will be 
a substantial increase in demand for thrombectomy in the near future. To provide more equal 
stroke care for patients living in different regions there is a need for a general policy. 
Different strategies will probably have to be implemented and combined, including improved 
and extended networks with access to rapid transportation, refined pre-hospital triaging with 
suitable patients with a high likelihood of harboring large artery occlusion transported 
directly to a comprehensive stroke center,163 and increased education and increased capacity 
to do interventional procedures, i.e. need for additional neurointerventionists. 
Studies have recently been made of costs and quality of life, in which patients receiving IVT 
and thrombectomy have been compared to patients receiving IVT alone.164-166 In Sweden, the 
Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, 
TLV) on behalf of the Swedish government conducted an investigation presented in the end 
of 2015, that showed that IVT plus thrombectomy is with high probability a cost effective 
treatment option for acute severe ischemic stroke.167 Part 2 of this investigation is to be 
presented to the government in December 2016, but the report was published in June 2016.168 
The last report investigated the possibilities and costs for transportation of patients from 
remote areas in Sweden to five (the situation today), six or seven (all University Hospitals of 
Sweden) tertiary centers where thrombectomy could be performed, depending on availability 
of neurointervention. The possibility of transportation with ambulances or helicopters was 
discussed. The conclusion was that thrombectomy in Sweden was cost effective even when 
helicopter transportation was needed, and the availability of neurointervention in more 
centers than currently (six or seven compared with five) would decrease the cost 
substantially. The possibility of rapid access to a center able to perform mechanical 
thrombectomy is essential; an analysis from data from the SWIFT-PRIME trial showed that 
with reperfusion later than 2.5 hours from symptom onset every subsequent hour decreased 
the possibility of functional independence with 20%.169 In larger cities one could also 
consider pre-hospital triage of patients with moderate to severe stroke, directing ambulances 
to hospitals able to perform thrombectomy. In mild to moderate stroke, the chance of good 
effect from IVT is higher, indicating that the possibility of helping these patients might be 
better at the closest hospital. This is a question in need of further evaluation.  
Recently, “European recommendations on organization of interventional care in acute stroke 
(EROICAS)” was published.170 Six European scientific societies (in alphabetical order: 
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European Academy of Neurology (EAN), European Association of Neurosurgical Societies 
(EANS), European Society of Emergency Medicine (EuSEM), ESMINT, ESNR, and ESO), 
have agreed on this consensus document regarding organization of interventional care in 
acute stroke. There are recommendations for many different steps during the care, for 
example which patients should be treated, by whom and how, preclinical and clinical 
requirements (discussing the question of direct transfer), and care after treatment. Notably, 
time from stroke onset to groin puncture should preferably be within 6 hours, and no later 
than 12 hours. No upper age limit and no limit in NIHSS score are recommended for 
thrombectomy and eligible patients should have a pre-stroke mRS score of 0-1.  
In study V, we show that the main challenge now is to fully implement mechanical 
thrombectomy in clinical practice and to provide access to this treatment not only to patients 
living in the proximity of university hospitals, but to all patients in Sweden 
 
6.7 WHICH STROKE PATIENTS SHOULD BE CONSIDERED FOR 
MECHANICAL THROMBECTOMY? 
There were different inclusion criteria in the randomized trials, for example in MR CLEAN 
patients could be included with milder symptoms (from NIHSS score 2) than in the other 
trials. This likely did not affect the result in any substantial way since the median NIHSS 
score is fairly similar in all these trials. In EXTEND-IA´s control group the median NIHSS 
score differs by being clearly lower than the others; 13 compared to 16-18 in the others. This 
might in part explain the superior results for the control group in EXTEND-IA (mRS 0-2 in 
40 %). The consistent high median NIHSS score among the other trials is interesting since it 
shows that patients with large vessel occlusions, eligible for thrombectomy, usually have 
severe symptoms. This is in line with the median score of 16 in our material, in which patient 
selection was not restricted to a study protocol. In Riksstroke annual report 2014 the NIHSS 
score was reported in 48% of stroke patients in all of Sweden.4 Among them the median 
NIHSS score was 3. There is obviously a large difference, showing that most patients with 
stroke will not be eligible for thrombectomy. Our results from study III demonstrate that 
larger groups of patients might benefit from thrombectomy, including wake-up strokes, but 
this would probably not affect the median NIHSS score in any substantial way.  
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Figure 23. NIHSS score at arrival to hospital, for stroke patients registered in Riksstroke 
2014.4 In red the median NIHSS scores for thrombectomy patients (according to study II and 
several studies in table 5). (Image is reprinted with permission from Riksstroke, figures and 
text in red are added by the author of this thesis) 
 
 
 
It is also worth noting the median ASPECTS, which is 9 in both the intervention group and 
the control group in three of the trials. In REVASCAT the median ASPECTS was 7 and 8, 
respectively, and in our study it was 8, indicating that a larger manifest infarction already 
existed before treatment and therefore making a complete recovery more unlikely in these 
studies compared to the others. It also shows that most often patients with no, or only minor 
manifest infarcts are selected for thrombectomy. In study III, where we discussed factors 
influencing the results, we found that we had a tendency to treat young patients (below 50 
years of age) with larger already manifest infarctions. In that age group 69% had an 
ASPECTS of 7 or below, but they still did significantly better at follow-up, with an odds ratio 
of 4.61 (1.34-15.9) for good functional outcome (mRS 0-2 at three months) compared to the 
age group 50-64. This might indicate a difference in potential for rehabilitation between age 
groups, and perhaps the need for age-differentiated selection criteria.  
Most studies, including ours, have focused on independence (mRS 0-2) as outcome measure. 
By now, the benefit of thrombectomy in large artery occlusion in the anterior circulation, as 
described above, is established. One can argue that the time has come to study the effect of 
thrombectomy on more severe stroke, with larger already manifest infarctions, for example 
ASPECTS <7 or even <5. If death or the most severe outcome (mRS 5-6) could be avoided 
with thrombectomy, a result of mRS 3 or even mRS 4 could be considered as good outcome. 
Or is the risk of a reperfusion hemorrhage too high, or the benefit too low? Is there a 
difference between age groups (considering the good results seen in study III for patients 
below 50 years of age and with low ASPECTS)? A randomized trial including this group of 
patients could be of great value. 
Frequency 
NIHSS 
score 
 
Median NIHSS scores for thrombectomy 
patients
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7 CONCLUSION AND FUTURE 
 
Our studies have showed that mechanical thrombectomy is a safe and effective treatment 
option for stroke caused by large artery occlusion in the anterior circulation, and that patients 
treated with mechanical thrombectomy in conjunction with IVT showed improved functional 
outcome and lower mortality than patients treated with IVT alone. The patients selected for 
treatment with thrombectomy usually suffer from a moderate to severe stroke, with a median 
NIHSS score around 16-18, have a verified occlusion of a large artery and absence of large 
manifest infarction, together indicating that there is a select group, and not all stroke patients, 
that will be eligible for thrombectomy.  
We have also shown that thrombectomy is safe and effective in the posterior circulation, with 
results surpassing those published for IVT. This, together with already proven good results 
for thrombectomy in the anterior circulation, makes the need for randomized trials in the 
posterior circulation ethically questionable. The efficacy and safety could be further 
investigated in observational or registry studies. For example, in Sweden all thrombectomies 
performed since 2013 are registered in a National quality registry, EndoVaskulär behandling 
av Akut Stroke (EVAS), which will enable nationwide research concerning thrombectomies 
in Sweden. The first annual report, from 2014, is available online.171 An international registry 
where thrombectomy patients can also be registered is the SITS Thrombectomy Register.172 
These registries provide excellent means to study mechanical thrombectomy in basilar artery 
occlusion without jeopardizing the health and lives of the patients, as might be the case in a 
randomized clinical trial. 
Patients aged above 80 years old as well as patients with wake-up stroke may experience a 
favourable outcome after thrombectomy, and should not be excluded from treatment. Future 
studies could well include patients with unknown time of symptom onset. It could also be 
interesting to consider age differentiated selection criteria, as well as study results for patients 
with lower pre-treatment ASPECTS. 
Other questions that need to be addressed, and that have not previously been discussed in this 
thesis, are for example whether to use conscious sedation or general anaesthesia, and how to 
approach more distal occlusions. Neuroprotective therapies might present a way to gain time 
for referral patients to reach a tertiary centre. Other areas where development can be expected 
are new intravenous thrombolytic drugs or adjuvant therapies, prevention of reperfusion 
injury and improvement of endovascular devices.173 
When the new treatment recommendations for large artery occlusion are fully implemented, 
an increased demand for mechanical thrombectomy can be expected. There is a need for 
policymakers, hospital administrators, and healthcare professionals to prepare for this 
increasing demand. This implies the need for general policies to provide as equal stroke care 
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as possible nationwide to all patients. In Sweden, the report from TLV on thrombectomy in 
acute severe ischemic stroke provides a foundation for that. In larger cities one could also 
consider pre-hospital triage of patients with moderate to severe stroke, directing ambulances 
to hospitals able to perform thrombectomy. In mild to moderate stroke, the likelihood of 
benefit from IVT is higher, indicating that the possibility of helping these patients might be 
better at the closest hospital. This is a question in need of further evaluation. 
Not only is there an urgent need for training of new neurointerventionists experienced enough 
to safely perform thrombectomy, but also for increased education of neurologists, stroke 
physicians, emergency physicians, nurses, paramedics and all other healthcare providers 
involved in patients with acute ischemic stroke. This is needed all over the country, not only 
at university hospitals, in order to provide as equal opportunities as possible, independent of 
who takes care of the patient first. An increased public awareness is also needed, in order to 
reduce the time from onset of symptoms to arrival to hospital. 
There are still many question to answer and details to study, but the advantages of 
thrombectomy in ischemic stroke caused by an acute large cerebral artery occlusion have 
been well proven. Our main challenge now is to fully implement the technique in clinical 
practice and to provide access to mechanical thrombectomy not only to patients living in the 
proximity of university hospitals, but to all patients in Sweden.  
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